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1. ABSTRACT 
 
Metabolism is defined as the sum of all biochemical reactions taking place in any 
given system at a specific point in time. Deregulation of metabolic balance in the 
human body can thereby have severe consequences in regard to health and well-
being. In mammals, proper storage and distribution of lipids in and between tissues 
is essential for the maintenance of energy homeostasis. Abnormally high levels of 
triglycerides (TG) in the blood (“hypertriglyceridemia”) represent a hallmark of 
disorders such as the Metabolic Syndrome, type 2 diabetes and atherosclerosis. 
Indeed, hypertriglyceridemia has been identified as an important risk factor for long-
term diabetic complications, whilst hypotriglyceridemia occurs in patients suffering 
from a tumour-associated wasting condition known as cachexia. 
 
In this study, we identify the hepatic transforming growth factor-beta 1 stimulated 
clone (TSC)-22 D4 as a critical molecular determinant of systemic lipid homeostasis 
and lipoprotein metabolism. Using a large-scale luminescence based mammalian 
interactome (LUMIER) screen, TSC22D4 was identified as an as-yet unknown 
interaction partner of the TBL1/TBLR1 transcriptional co-factor complex. TSC22D4 
was found to be down-regulated under conditions of diet-induced obesity and 
induced in cancer cachexia. Liver-specific ablation of TSC22D4 in mice triggered 
serum hyperlipidemia through the induction of lipogenic gene expression in the liver 
and an associated increase in the release of TG-rich very-low-density-lipoprotein 
(VLDL) particles. Conversely, restoration of TSC22D4 in obese mice led to reduced 
VLDL release and TG accumulation in the liver. 
 
TSC22D4 expression levels were found to inversely correlate with the degree of 
weight loss in a mouse model of cancer cachexia. In future, it will be interesting to 
investigate if the induction of hepatic TSC22D4 activity represents a cause or 
protective consequence in the onset of tumour-associated cachexia. In this regard, 
TSC22D4 may serve as a molecular marker for disease progression and prognosis in 
patients. 
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2. ZUSAMMENFASSUNG 
 
Der Stoffwechsel umfasst die Summe aller biochemischen Reaktionen, die zu einer 
bestimmten Zeit in einem Organismus stattfinden. Ist das metabolische 
Gleichgewicht im menschlichen Körper gestört, hat dies schwerwiegende 
Auswirkungen auf die Gesundheit und die Lebensqualität. Dabei, ist die effiziente 
Speicherung und der geregelte Transport von Lipiden zwischen verschiedenen 
Geweben bei der Koordination des Energiehaushalts von großer Bedeutung. Erhöhte 
Triglyzeridspiegel im Blut sind ein Kennzeichen des metabolischen Syndroms. Sie 
treten vermehrt bei Typ 2 Diabetes und Arteriosklerose auf. Während 
Hypertriglyzeridämie ein wichtiger Risikofaktor bei chronisch diabetischen 
Komplikationen ist, tritt Hypotriglyzeridämie hingegen vor allem bei 
Krebskachexiepatienten auf. 
 
In dieser Arbeit zeigen wir, dass das Gen ‘Transforming growth factor-beta 1 
Stimulated Clone (TSC)-22 D4’ ein wichtiger molekularer Schalter in der Regulation 
des Lipidstoffwechsels darstellt. Mit Hilfe eines Hochdurchsatzverfahrens wurde eine 
Interaktion zwischen TSC22D4 und den transkriptionellen Kofaktoren TBL1 und 
TBLR1 identifiziert. Die Expression von TSC22D4 ist in diabetischen Mausmodellen 
reduziert und bei Krebskachexie erhöht. Leberspezifische Knock-Down-Studien in 
Mäusen führten zur Induktion der Lipogenese, erhöhten Triglyzeridwerten im Blut 
und einer verstärkten Sekretion von Lipoproteinen geringer Dichte (VLDL). 
Überexpression von TSC22D4 in diabetischen Mäusen hingegen, resultierte in 
reduzierter Lipogenese, geringerer VLDL-Sekretion und einer Akkumulation von 
Triglyzeriden in der Leber. 
 
Die TSC22D4-Expression korrelierte mit dem Verlust an Körpergewicht bei einem 
Mausmodel der Krebskachexie. Zukünftige Forschungen werden zeigen, ob die 
Induktion der TSC22D4-Aktivität in der Leber eine Ursache, oder eine schützende 
Konsequenz bei der Pathogenese der tumorassoziierten Kachexie darstellt. In diesem 
Zusammenhang könnte TSC22D4 als Marker für Progression und Prognose bei 
Krebspatienten dienen. 
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3. INTRODUCTION 
 
In the past century, biotechnology and translational medical research have made 
great advances. Previously deadly diseases are manageable and subsequently people 
are living to a much higher age. This progress has however not only led to 
demographic problems, but also given rise to new health issues. Aging diseases, such 
as type 2 diabetes are becoming increasingly prevalent, especially as excess caloric 
intake and reduced exercise are common in our developed world. While it is 
important to educate the population on how to prevent the onset of metabolic 
disorders, mainly through a healthy life style, it is also necessary to understand the 
underlying molecular and physiological processes. Metabolic signalling and 
transcriptional control thereby represent potent switches in the natural or 
pharmacological control and regulation of a healthy metabolic state. This dissertation 
will therefore focus on novel regulatory components of liver physiology. 
 
 
3.1 Metabolic Disorders 
 
 
3.1.1. Obesity 
 
During evolution, mammals have acquired intricate mechanisms to absorb, process 
and store nutrients. The ability to build energy depots for times of low food 
availability has thereby been essential for the survival and development of complex 
organisms (1). Undoubtedly, even today a large part of the world wide population, 
especially in western Africa, suffers from undernutrition and is heavily reliant on 
these energy depots (2). In recent years however, a new metabolic problem has 
become increasingly obvious. Excessive calorie intake, in combination with a 
sedentary life style, has led to an obesity pandemic in developed and developing 
countries (Fig. 1). Globally, overweight and obesity cause more deaths than 
undernutrition. Current estimates from the World Health Organization (WHO) 
suggest that in 2008, 1.5 billion adults were overweight and 500 million were 
considered obese, representing 10% of the population. What seems even more 
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alarming is that, today 43 million children under the age of 5 are estimated to be 
overweight (I). 
 
  
 
 
 
 
An individual is considered overweight if his or her body mass index (BMI = weight 
[kg]/ (height [m])2) is above 25 and obese if the BMI is higher than 30. Several 
medical conditions are associated with obesity. The permanent over-supply of food 
particularly favours the development of insulin resistance, type 2 diabetes mellitus, 
hypertension, organ damage, atherosclerosis and cardiovascular disease (3). Apart 
from these ‘traditional’ metabolic diseases, the link between cancer and obesity is also 
becoming increasingly evident. Hormones and growth factors, such as insulin, are 
hypersecreted and induce cell proliferation. In particular, liver, breast and colon 
cancer incidence are highly associated with excess body weight (4,5). 
 
Obesity has many underlying social and genetic causes. Today large parts of the 
population consume processed, energy-dense food with low nutritional value. In 
combination with a sedentary lifestyle and low energy expenditure, the effects on the 
body are deleterious. Whilst extremely rare monogenic conditions do exist, in most 
cases obesity stems from a combination of environmental and genetic factors. Many 
susceptibility genes have been discovered and described in great detail. However, 
individual susceptibility genes only account for a small portion of obesity cases, since 
the genetic basis is multigenic and combinatorial. Nevertheless, by understanding the 
Fig. 1: Increase in obesity incidence. Prevalence of obesity in men (A) and women (B) in 1980 
(blue) and 2008 (red). Taken from Ahima 2011. 
A) B) 
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mechanisms by which such genes function, it will be possible to develop medical 
intervention strategies to prevent the onset of obesity at an early stage (1,6,7).  
 
3.1.2. The Metabolic Syndrome, insulin resistance and Type 2 diabetes 
mellitus 
 
Visceral obesity is the primary indicator for a loosely defined condition known as the 
Metabolic Syndrome or Syndrome X. Apart from central obesity, the Metabolic 
Syndrome is characterized by dyslipidemia, hypertension, hyperglycaemia and 
chronic low-grade inflammation. The condition is, amongst other things, associated 
with cardiovascular disease, type 2 diabetes mellitus, hepatic steatosis and gall stone 
disease. Individuals suffering from the Metabolic Syndrome have a 5-fold higher risk 
of developing non-insulin dependent type 2 diabetes mellitus (8,9). 
 
 
 
 
 
 
 
 
 
 
 
Patients suffering from type 1 diabetes mellitus are generally not obese. They have an 
autoimmune disease that destroys the pancreatic β-cells required to produce the 
peptide hormone insulin. Subsequently, they are absolutely dependent on injected 
insulin to regulate glucose homeostasis (10). The majority of diabetes patients (~ 
90%) suffer from non-insulin dependent type 2 diabetes mellitus, a condition in 
which the β-cells are initially healthy. The disease, which is tightly associated with 
obesity and the Metabolic Syndrome, is characterized by insulin resistance of 
peripheral organs such as the brain, muscle, liver and adipose tissue. As in the case of 
obesity, the incidence and economic burden are increasing dramatically (Fig. 2) and 
Fig. 2: Prevalence of 
diabetes 2010. Global 
incidence of type 2 
diabetes mellitius in the 
year 2010. Taken from 
(II). 
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what was once considered an aging disease is now commonly being diagnosed in 
children (11-13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
It is important for the body to maintain normoglycemia, with blood glucose levels in a 
physiological range (~ 5 mM). Glucose metabolism is regulated by insulin and its 
antagonist glucagon. After food consumption, the pancreatic β-cells sense the 
elevation in blood glucose via low affinity Glut2 glucose transporters and 
subsequently release insulin. The hormone induces signalling cascades, resulting in 
glucose uptake by muscle, fat and liver and inhibition of hepatic glucose production 
(gluconeogenesis) and release. At the same time, it inhibits triglyceride (TG) break 
down (lipolysis) in adipose tissue and instead promotes the conversion of glucose to 
lipids (lipogenesis). If, upon fasting or exercise, blood glucose levels sink below a 
threshold, insulin is no longer secreted and instead glucagon is released by pancreatic 
α-cells. Glucagon induces glucose production and secretion by the liver (14). In the 
case of insulin resistance, this tightly regulated circuit is compromised. Postprandial 
and fasting glucose and fatty acid levels are elevated, leading to the release of more 
and more insulin. Insulin signalling is blunted, muscle and liver inefficiently import 
and convert glucose and hyperglycaemia occurs due to the reduced inhibition of 
gluconeogenesis. Lipolysis is not inhibited in adipose tissue, leading to the release of 
non-esterified free fatty acids. These circulating fatty acids then accumulate in the 
liver, where they are converted to TGs and induce hepatic steatosis (Fig. 3). All these 
processes subsequently accelerate the manifestation of severe insulin resistance. At 
Fig. 3: Obesity and insulin 
resistance. Insulin resistance leads 
to elevated lipid release by liver and 
adipose tissue. Excess glucose is 
produced by the liver and glucose 
uptake by muscle is impaired. 
Elevated serum glucose and lipid 
levels further aggravate the overall 
condition. 
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first, the pancreas can compensate for reduced insulin sensitivity by releasing more 
insulin, but over time the capacity is exhausted and patients develop full-blown type 
2 diabetes mellitus, making them dependent on injected insulin (15). 
 
3.1.3. Cancer cachexia 
 
Cancer and immune suppressing diseases, such as AIDS, induce major changes on 
whole body glucose, lipid and protein metabolism (16,17). Many cancer entities are 
indeed accompanied by a condition known as cachexia (Greek ‘kakos hexis’ meaning 
bad condition). Cancer cachexia is characterized by severe weight loss, primarily due 
to lean muscle and adipose tissue wasting, bad prognosis and a reduced quality of 
life. Pancreatic and lung cancer are particularly often associated with cachexia and 
the condition is responsible for approximately 20% of all cancer related deaths (18).  
 
Although cachexia patients suffer from appetite loss, anorexia cannot fully explain 
the observed weight loss, as food supplementation does not stop progression. In 
healthy individuals, resting energy expenditure (REE) accounts for up to 70% of 
energy consumption. REE is strongly increased in cachectic patients. This is in part 
due to increased expression of so-called uncoupling proteins (UCPs) in muscle and 
adipose tissue. These mitochondrial membrane components relieve the membrane 
potential before oxidative phosphorylation can take place. This process leads to the 
production of heat rather than energy in the form of adenosine triphosphate (ATP). 
Indeed, in recent years it has been shown that energy storing white adipose tissue can 
be transformed into energy-consuming brown-like adipose tissue in a process known 
as browning. The transformation results in a depletion of energy and body mass (19). 
In addition, lipolysis is induced in cachectic individuals’ adipose tissue and the 
released free fatty acids in turn are fed into futile cycles such as the hepatic Cori cycle, 
leading to further calorie consumption (20). Muscle mass is also greatly reduced in 
cachexia, as protein synthesis is inhibited and protein breakdown is enhanced. The 
catabolic effects, in particular ubiquitin dependent proteolysis, thereby seem to be 
rate limiting (21). Although most focus in cachexia research has been on muscle and 
adipose tissue, the liver is also important in the manifestation of the disease. It serves 
as a sink for the fatty acids released from adipose tissue. Subsequently the liver 
accumulates fat and reduces de novo TG secretion (22).  
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Taken together, cachexia represents a complex pro-inflammatory metabolic disorder 
affecting systemic glucose, lipid and protein metabolism. There are, as of now, few 
therapeutic options to treat the disease, making it necessary to investigate the 
condition in more detail (21,23). 
 
 
3.2 Lipid metabolism 
 
 
3.2.1. Liver lipid metabolism 
 
The liver is the largest internal organ and crucial for the regulation and distribution 
of carbohydrates, lipids and proteins. Apart from hepatocytes (~ 80% of cells), the 
liver contains immune reactive macrophages (Kupffer cells), natural killer cells (pit 
cells), endothelial cells and pericytes (stellate cells). It is supplied with blood via the 
portal vein, which transports nutrients as well as waste products, such as hormones 
or drugs. The liver is the designated organ for the production and release of bile 
acids, cholesterol and specific serum proteins, such as albumin. One of the liver’s 
primary functions is the regulation of glucose metabolism. Postprandial insulin 
signals for excess glucose to be transported into hepatocytes and stored in the form of 
glycogen. At times of need, these stores are utilized to maintain normoglycemia 
(24,25). 
 
Systemic lipid metabolism is largely coordinated by the liver. Fatty acids are taken up 
by transporters (e.g. CD36) on the membranes of hepatocytes, in proportion to their 
concentration in the serum. Within the cell, they are bound by fatty acid binding 
proteins and either oxidized or processed to form neutral lipids. Fatty acid oxidation 
(𝛽-oxidation) takes place in the mitochondria, or in the case of very long chain fatty 
acids, the peroxisomes. During this process, fatty acids are broken down into acetyl-
CoA molecules which are then fed into the citric acid cycle, or used to synthesize 
steroids, such as cholesterol. Incomplete 𝛽-oxidation results in the production of 
ketone bodies as an alternate energy source. The liver is not only capable of breaking 
down fatty acids, but is also important for fatty acid and TG biosynthesis. After two 
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acetyl-CoA molecules have been linked, forming malonyl-CoA, a sequence of 
condensation reactions takes place, ultimately resulting in the biogenesis of long 
chain fatty acids. These molecules are then linked to glycerol, forming TGs, which are 
either stored in the liver or released into the blood stream as components of very low 
density lipoprotein particles (VLDL) (26-28). 
 
 
 
 
 
 
 
 
 
 
 
Obesity and type 2 diabetes mellitus not only deregulate hepatic glucose, but also 
lipid metabolism. Due to increased lipolysis in adipose tissue, more non-esterified 
free fatty acids are imported into the liver and inhibit insulin signalling. As insulin 
resistance also induces hepatic lipogenesis, the balance of lipid influx versus lipid 
efflux is disturbed and fat accumulates within hepatocytes. Indeed, non-alcoholic 
fatty liver disease (NAFLD) is common amongst diabetes patients and represents a 
hallmark of the Metabolic Syndrome. In many cases, NAFLD leads to scarring of the 
liver, non-alcoholic steatohepatitis (NASH) and ultimately liver cirrhosis or failure 
(Fig. 4). As mentioned above, the liver also acts as a sink for lipids released by 
adipose tissue in cancer cachexia, again inducing hepatic steatosis (22,29,30). 
 
3.2.2. Lipoprotein metabolism and dyslipidemia 
 
TGs and cholesterol are transported through the blood stream by macromolecular 
complexes known as lipoprotein particles. Their surface is composed of amphipathic 
phospholipids, which surround a core, containing hydrophobic TGs and cholesterol 
esters. The particles are classified according to their density, which in combination 
Fig. 4: Progression of fatty liver disease. In obesity and insulin resistance, the liver accumulates 
increasing amounts of fat, as non-esterified free fatty acid (NEFA) uptake is increased and very low 
density lipoprotein (VLDL) secretion is reduced. This first leads to the development of non-alcoholic 
fatty liver disease (NAFLD), then to non-alcoholic steatohepatitis (NASH) and in many cases finally to 
liver cirrhosis and cancer. 
 Healthy liver                      NAFLD                                 NASH                    Cirrhosis / cancer 
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with the apolipoprotein composition, determines their further fate. Whilst there are 
several sub-categories, lipoprotein particles are generally classed in the four major 
categories stated below (Tab. 1) (31). 
 
Lipoprotein 
species 
Abbreviation Primary 
apolipoprotein 
Triglyceride 
content [%] 
Cholesterol 
content [%] 
High density HDL ApoA I-V ~ 7.5 ~ 20 
Low density LDL ApoB100 ~ 7.5 ~ 45 
Very low density VLDL ApoB100 ~ 70 ~ 7.5 
Chylomicrons Chylo. ApoB48 ~ 90 ~ 5 
 
 
Chylomicrons are lipoprotein particles which contain TGs and cholesterol originating 
from food. They are produced by the intestine and provide muscle and adipose tissue 
with energy. Their major protein component is apolipoprotein B (ApoB) 48, an 
isoform containing 48% of the full-length ApoB coding sequence. Once they have 
been depleted of TGs, their remnants are taken up by the liver (32). Very low density 
lipoproteins (VLDL) have a similar structure, but are synthesized endogenously by 
the liver and released into the blood stream. VLDL assembly takes place in the 
endoplasmatic reticulum (ER) and is strictly regulated by TG availability and 
regulatory proteins such as microsomal TG transport protein (MTP). During 
biosynthesis of full length ApoB100, the main protein component of VLDL, TGs and 
cholesterol are added to the particles, which are then secreted by the liver (33). 
Circulating VLDL is hydrolyzed by lipoprotein lipase (LPL), providing adipose tissue 
and muscle with energy in the form of fatty acids. Consequently, the density of the 
particles increases, apolipoproteins are exchanged and low density lipoprotein 
particles (LDL) are formed and recycled by the liver. Excess cholesterol is removed 
from the periphery by high density lipoprotein particles (HDL) that originate from 
the liver. In a process referred to as reverse cholesterol transport, these particles 
scavenge cholesterol and deliver it to the liver for processing. Uptake is primarily 
performed by low density lipoprotein receptor (LDLR) that has high affinity for 
apoprotein E (ApoE), a component integrated into HDL and LDL (34,35). 
 
 
 
Tab. 1: Characteristics of different lipoprotein species (Adapted from Ginsberg et al. 2004). 
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Dyslipidemia describes a pathogenic condition characterized by deregulated, usually 
elevated, blood lipid content. In obese and insulin resistant individuals, lipoprotein 
metabolism is disturbed, primarily due to increased VLDL secretion by the liver. This 
is most likely due to elevated serum fatty acid levels, excess TGs resulting from 
enhanced hepatic lipogenesis and increased uptake of TG containing chylomicron 
and VLDL remnants (Fig. 5). Indeed, insulin resistant patients display a 
characteristic pro-atherogenic lipoprotein profile defined by elevated LDL and VLDL 
TG levels in combination with reduced HDL content. Such a profile not only 
accelerates the onset of insulin resistance, but also favours the manifestation of 
cardiovascular disease and atherosclerosis (36,37). Over time, excess VLDL is 
processed by cholesteryl-ester transfer protein (CETP). TGs and cholesterol are 
thereby exchanged between VLDL and HDL, leading to a reduction of ‘good’, 
cholesterol scavenging HDL and an accumulation of ‘bad’ small dense cholesterol 
containing LDL particles. These LDL particles are pathogenic, due to their reduced 
affinity for hepatic lipoprotein transporters, a higher capacity of binding to arterial 
walls and increased susceptibility to oxidation (38,39). Oxidized LDL can no longer 
be cleared by the liver. Instead, it is removed by macrophages via phagocytosis. Due 
to their morphology, the resulting cells are referred to as foam cells. Over time they 
enter and accumulate in the arterial wall and form atherosclerotic plaques due to an 
inflammatory response. Consequently, blood flow is reduced, increasing the risk of 
infarctions in the heart, brain or other vital organs (40). 
 
 
 
 
Fig. 5: Very low density lipoprotein 
metabolism. Very low density lipoprotein (VLDL) 
particles are generated in the liver. Output is 
coordinated by apolipoprotein B (ApoB) synthesis, 
intracellular triglyceride (TG) content, the rate of 
lipogenesis and import of non-esterified free fatty 
acids (NEFA) and low density lipoprotein (LDL) 
particle remnants from the serum. All these stimuli 
are increased in obesity and type 2 diabetes 
melltitus. Adapted from Ginsberg et al. 2004. 
INTRODUCTION 
 
12 
 
3.3 Cellular signalling 
 
 
 
3.3.1. Transcriptional regulation 
 
The ability to recognize external signalling molecules and to coordinate a precise 
intracellular response has been a prerequisite for the evolution of multi-cellular life. 
Over time, complex cellular machinery encompassing cell-surface receptors, 
activators, enzymes and substrates has evolved and become essential for relaying 
extracellular messages to intracellular effectors. Dynamic formation of signal-
dependent protein structures, rapid signal transduction via preassembled multi-
protein complexes, sub-cellular localization and temporal availability, have thereby 
proven to be crucial for efficient signalling (41). Signals are transmitted by numerous 
mechanisms, predominantly leading to conformational changes or protein 
modifications. Phosphorylation of proteins, for example, may deem them accessible 
for interaction partners or render them functionally active. Once a signal has reached 
the nucleus, it often induces changes in the cell’s transcriptional profile. This process 
is primarily governed by transcription factors that bind directly to DNA. The 
mammalian genome contains almost 1000 individual transcription factors that, in 
combination with the basal transcriptional machinery, DNA binding factors, 
chromatin remodelling complexes, co-factors and histone modifying enzymes, 
precisely regulate gene expression (42,43). 
 
Nuclear receptors are a subset of transcription factors that are activated by ligand 
binding and act as a direct link between the extracellular environment and gene 
expression. The ligands are small molecules such as steroid hormones, bile acids or 
lipids. They enter the cell and its nucleus via diffusion or translocation. As far as we 
know, the human genome encodes 48 nuclear receptors. All of them have a 
characteristic structure, consisting of an N-terminal activation domain, a conserved 
central DNA-binding domain and a C-terminal ligand binding domain (44). Nuclear 
receptors have precise tissue-specific expression patterns and only bind to prototypic 
DNA sequences (response elements), usually upstream of a target gene’s promoter 
(45). Due to their tissue-specificity and their crucial relevance in governing energy 
metabolism, nuclear receptors have long been in the focus of biomedical research. 
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Synthetic peroxisome proliferator activated receptor (PPAR) γ ligands 
(rosiglitazones) effectively counteract insulin resistance and dyslipidemia. However, 
as rosiglitazones have severe side-effects other nuclear receptors are being 
investigated as potential drug targets. The PPARδ ligand GW501516, for example, has 
shown very promising results regarding systemic glucose and lipid homeostasis and 
is currently being tested in phase I clinical trials (46). 
 
Nuclear receptors and transcription factors do not act alone in controlling gene 
expression, but instead are components of large multi-protein regulatory complexes. 
These complexes regulate DNA accessibility and subsequently transcriptional 
capacity. Chromatin structure depends on DNA methylation status, chromatin 
composition and the presence of histone modifications. By adding or removing 
specific residues to histone tails, chromatin remodelling enzymes determine how 
densely or loosely chromatin is packed. In this context, histone deacetylation leads to 
tightly packed inaccessible chromatin and histone hyperacetylation loosens the 
structure and facilitates transcription (47). Chromatin remodelling enzymes are 
recruited to the vicinity of DNA by co-regulators that induce transcriptional 
activation (co-activators) or repression (co-repressors). Nuclear receptor co-repressor 
(N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) 
are two prototypical co-repressors with high sequence homology (48,49). Both 
contain a bipartite nuclear receptor interaction domain, but can also interact with 
conventional transcription factors. The co-repressors are at the centre of large multi-
protein complexes containing the enzymatic component histone deacetylase (HDAC) 
3. By removing acetyl residues from histone tails, this enzyme uncovers positively 
charged surfaces that interact with the negatively charged DNA and compress the 
chromatin structure (Fig. 6). N-CoR and SMRT bind unligated nuclear receptors, 
thereby inhibiting transcription. When a ligand binds to the nuclear receptor, the co-
repressor is dismissed and co-activators and histone acetyl transferases (HAT) 
interact with the nuclear receptor. Subsequently chromatin is remodelled into the 
loose, accessible form (Fig. 6). Often, active mechanisms such as phosphorylation or 
ubiquitin dependent dismissal are required to enable the switch from a repressive to 
an active state. This process is known as de-repression. Nuclear receptors and co-
regulators have been implicated in the development of several metabolic disorders 
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and cancer entities, making them attractive targets when trying to understand and 
combat these diseases (42,50,51). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2. Transducin beta like 1 and transducin beta like 1 related 
 
Transducin beta like 1 (TBL1) is a gene located on the human X-chromosome. It was 
initially described in the context of sensorineural deafness, a hearing disorder that 
occurs primarily in middle aged men and is associated with deletions in the TBL1 
gene (52,53). TBL1 shares almost 90% sequence homology with another protein, 
transducin beta like 1 related (TBLR1). Structurally, both proteins posses an N-
terminal LisH domain, followed by an F-Box domain and six C-terminal WD40 
repeats which form a propeller structure. TBL1 and TBLR1 directly interact with the 
N-CoR/SMRT N-termini via their LisH domains and are involved in the repression of 
gene expression (54). The co-repressors interact with histones H2A, H3 and H4, 
making them accessible for HDAC3, which is also incorporated in the N-CoR/SMRT 
complex. Subsequently, histones are hypoacetylated and transcription is repressed 
(55-57). Interestingly, TBL1 and TBLR1 are not only required for repression, but also 
Fig. 6: Transcriptional control. Unligated nuclear receptors (NR) are bound to co-repressor 
complexes that recruit histone deacetylase (HDAC) 3, leading to hypoacetylated, tightly packaged 
DNA. Upon ligand binding, the co-repressive structures are dismissed. Co-activators and histone 
acetyl transferases (HAT) are recruited, leading to hyperacetylated (AC), accessible chromatin.  
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for signal-dependent dismissal of co-repressors and subsequent activation of gene 
expression. Both proteins serve as E3 ubiquitin ligases that recruit E2 ubiquitin 
conjugating enzymes, such as UbcH5-E2, leading to ubiquitination and ultimately 
degradation of co-repressors by the proteasome. Furthermore, TBL1 and TBLR1 have 
been shown to actively recruit co-activators including Rip140 and CBP, hence their 
description as nuclear receptor co-repressor / co-activator exchange factors (58) (Fig. 
7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initially TBL1 and TBLR1 were considered to be functionally redundant. Recent 
studies have however shown that they have distinct functions, primarily regulated by 
phosphorylation sites specific to one or the other protein. In this regard, TBLR1 for 
example seems to be the ubiquitin ligase required for de-repression of N-CoR/SMRT, 
whilst TBL1 is required to dismiss the co-repressor C-terminal-binding protein (Ctbp) 
(Fig. 7). Many genes are repressed by both N-CoR/SMRT and Ctbp at the same time, 
Fig. 7: Nuclear receptor co-repressor / co-activator exchange factors TBL1 and TBLR1. 
Unligated nuclear receptors (NR) are associated with co-repressor complexes containing N-
CoR/SMRT, Ctbp, HDAC3, TBL1 and TBLR1. Upon ligand binding, TBLR1 recruits the E2 
ubiquitin conjugating enzyme UbcH5 to N-CoR/SMRT. TBL1 targets the same enzyme to Ctbp. 
UbcH5 interacts with the 19 S proteasome and subsequently, the co-repressor complexes are 
dismissed and degraded by the 26 S proteasome. TBL1 and TBLR1 then actively recruit co-
activator complexes and histone acetyl transferases (HAT). 
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implementing a dual checkpoint to be passed during signal dependent gene activation 
(59). Nuclear receptors are not the only transcription factors regulated by TBL1 and 
TBLR1. Several other pathways, including the canonical wnt signalling cascade have 
also been linked to the two co-factors. Indeed, TBL1 and TBLR1 have been shown to 
recruit the wnt associated protein β-catenin to hypoacetylated target gene promoters 
and facilitate gene expression driven by the transcription factor TCF. The direct 
interaction with TBL1 and TBLR1 furthermore protects β-catenin against ubiquitin 
dependent proteasomal degradation, as the binding site for E2 ubiquitin conjugating 
enzymes is hidden. Wnt signalling promotes cell proliferation and can induce tumour 
formation, implying that TBL1 and TBLR1 may be involved in this process (60-62).  
 
It was recently shown that TBL1 and TBLR1 play a crucial role in the regulation of 
hepatic lipid metabolism. Mice lacking the two proteins in their livers develop severe 
hypertriglyceridemia and hepatic steatosis, as de novo lipogenesis in the liver is 
increased and β-oxidation is reduced (63). To understand the mechanisms 
underlying this phenotype in more detail, it is necessary to identify and investigate 
proteins that interact with TBL1 and TBLR1 in the liver.  
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4. AIM OF THE STUDY 
 
 
The Metabolic Syndrome affects a large part of the world wide population and its 
prevalence is ever increasing. In recent years it has become more and more evident 
that both environmental and genetic parameters influence the integrity of 
transcriptional networks that are crucial in maintaining a healthy metabolic status. 
The precise molecular mechanisms are however still largely enigmatic.  
 
The aim of this study was to perform a luminescence-based mammalian interactome 
mapping (LUMIER) screen and discover novel interaction partners of TBL1 and 
TBLR1, two proteins known to play important roles in the regulation of liver lipid 
homeostasis. After identifying and confirming a new TBL1 / TBLR1 interaction 
partner, we intended to functionally characterize the relevance of this novel target 
gene by employing in vivo loss and gain of function studies. Furthermore, the 
regulation of the novel TBL1 / TBLR1 interacting protein was to be investigated in 
various models of metabolic stress and dysfunction. The experimental design is 
described in Fig. 8. 
 
1. Screen for novel TSC22D4 interaction partners
 →  LUMIER SCREEN 
→  Validation using alternative biochemical    
      methods 
 
2. Identify liver-specific in vivo relevance of the 
newly identified interaction partner 
 
→  Expression analysis in mouse models 
→  In vivo knock down / over expression   
      studies 
 
3. Identify translational relevance 
 →  Correlate results to human metabolic  
pathologies   
Fig. 8: Experimental design overview  
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5. RESULTS 
 
5.1 TSC22D4 is a novel TBL1 and TBLR1 interaction partner 
 
 
5.1.1. Luminescence-based mammalian interactome mapping (LUMIER) 
screen for novel TBL1 and TBLR1 interacting proteins 
 
Both TBL1 and TBLR1 have been shown to play important roles in hepatic lipid 
metabolism (63). In this regard, liver-specific ablation of either protein leads to the 
development of hepatic steatosis and hypertriglyceridemia. Further, TBL1 expression 
is not only reduced in diabetic animal models, but also inversely correlates with liver 
TG content in humans suffering from non-alcoholic steatohepatitis (NASH).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to further investigate the precise mechanisms by which TBL1 and TBLR1 
partake in transcriptional control and the regulation of metabolic processes, it is 
important to identify and characterize their associated proteins. To this end, a 
luminescence-based mammalian interactome mapping (LUMIER) screen was 
employed to identify novel TBL1 and TBLR1 interaction partners. Using this high 
Fig. 9: Luminescence-
based mammalian 
interactome mapping 
(LUMIER). Prey proteins 
were cloned into a reporter 
construct expressing Renilla 
Luciferase and co-
transfected into HEK293T 
cells with a library of 
Protein-A tagged nuclear 
proteins in a 96 well format. 
Positive protein-protein 
interactions resulted in 
measureable luciferase 
activity above background 
after protein purification 
using IgG coated magnetic 
beads. If no interaction took 
place, the luciferase-tagged 
bait was lost during washing 
and no signal above 
background was detected. 
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throughput co-immunoprecipitation procedure, it was possible to rapidly screen for 
protein-protein interactions in a mammalian system (64). HEK293T cells were co-
transfected with Renilla Luciferase-tagged TBL1 or TBLR1 and a library of 605 
different nuclear proteins fused to a Protein-A tag. After cell lysis and purification of 
the Protein-A-tagged bait using IgG beads, positive interactions were identified by 
measuring the luciferase signal, after the addition of luciferin. Only if the bait and 
prey proteins interacted, could luminescence be detected. The well characterized 
interactions between FOS and JUN, as well as TBL1 and TBLR1, served as positive 
controls, for assay integrity. A model for the experimental set-up employed in this 
study is shown in Fig. 9. 
 
The luciferase signals resulting from the positive control reactions were significantly 
above background, demonstrating that true interactions could be detected using the 
LUMIER method (Fig. 10A). These values also served as references when judging the 
results obtained during screening and determining cut-off values, above which an 
interaction was considered to be likely. Luciferase-tagged TBL1 co-precipitated with 
several members of the nuclear protein library, resulting in luminescense signals 
significantly above background. The strongest interactions were observed with the 
proteins CRTC1, MAFK, NRF1, RRM2, RYBP TRIM27, TRIM32, TSC22D1, TSC22D4, 
VGLL1, WRNIP1 and ZFP36L2 (in alphabetical order). The highest luciferase signal 
was thereby detected after co-transfection of tagged TBL1 and TGFβ stimulated clone 
(TSC) 22 domain family, member 4 (TSC22D4; Fig. 10A).  
 
To verify the obtained results, the assay was repeated several times with the twelve 
top scoring candidate proteins. In all cases a strong interaction between TSC22D4 
and TBL1 was detected (Fig. 10B). Indeed, the TBL1-TSC22D4 interaction 
consistently delivered stronger signals than both the FOS-JUN and the TBL1-TBLR1 
positive control assays, indicating that this interaction is true and worthy of further 
investigation. 
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Fig. 10: Novel TBL1 interaction partners were identified by LUMIER screen. LUMIER assays 
were performed with luciferase-tagged TBL1 and an array of 605 different nuclear protein 
expression constructs. The Y-axis represents z-scores and colours indicate individual 96-well 
plates. Stars represent TBL1- TBLR1 binding as a positive control. Selected hits, including the 
interaction between TBL1 and TSC22D4, are labeled (A). The top hits resulting from the TBL1-
screen were re-assessed and the interaction between TBL1 and TSC22D4 was verified in several 
independent experiments. Each blue spot represents an individual assay (B). 
 
TSC22D4 
TSC22D1 ZFP36L2 
CCHCR1 
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Next, the LUMIER screen was performed using luciferase-tagged TBLR1 as prey and 
the same library of Protein-A tagged nuclear proteins as bait. As TBL1 and TBLR1 
share over 90% protein sequence homology (65), it is likely that they posses certain 
common interaction partners. As expected, a strong interaction between TBLR1 and 
TSC22D4 was observed in the screen. The obtained luciferase signals were again 
significantly higher than those resulting from the positive controls, strengthening the 
notion that TSC22D4 is incorporated in complexes harbouring TBL1 and TBLR1 (Fig. 
11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Little is known about the in vivo characteristics and tissue-specific importance of 
TSC22D4 and no studies have so far described this gene in a metabolic context. The 
protein has however, like TBL1 and TBLR1, been shown to be involved in 
transcriptional repression (66), making it an interesting candidate for further in vivo 
analysis. Before investigating the functional relevance of TSC22D4, it was however 
first necessary to further verify the interaction with TBL1 and TBLR1 using multiple 
biochemical methods. 
 
 
 
Fig. 11: Novel TBLR1 interaction partners were identified by LUMIER screen. LUMIER 
assays were performed using luciferase-tagged TBLR1 and a library consisting of 605 nuclear 
proteins. The Y-axis represents z-scores and colours indicate individual 96-well plates. Stars 
represent TBL1- TBLR1 binding as a positive control. Selected hits, including the interaction 
between TBLR1 and TSC22D4, are labeled. 
 
ZFP36L2 
CCHCR1 
TSC22D1 
TSC22D4 
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5.1.2. Verification of the interaction between TSC22D4 and TBL1 / 
TBLR1 by Flag co-immunoprecipitation 
 
Flag co-immunoprecipitation studies were performed to prove that the newly 
identified interaction between TBL1, TBLR1 and TSC22D4 was true. In this setting, it 
was important to use different affinity tags to those used in the LUMIER assays, to 
exclude that the Renilla Luciferase and Protein-A polypeptide sequences had 
influenced heterodimer formation and led to false positive results during screening. 
HEK293 cells were co-transfected with Flag-tagged TBL1, Flag-tagged TBLR1 or the 
Flag-tag alone in combination with Myc-tagged TSC22D4. After cell lysis, the Flag-
tagged proteins were immunoprecipitated using an anti-Flag affinity resin. Only in 
the presence of the Flag-TBL1 or Flag-TBLR1 fusion-proteins, was it possible to co-
precipitate Myc-TSC22D4, supporting the notion that TSC22D4 and TBL1 / TBLR1 
interact with one another (Fig. 12). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: TSC22D4 co-precipitates with TBL1 and TBLR1 in Flag co-
immunoprecipitation studies. For co-immunoprecipitation studies, HEK293 
cells were transfected with Myc-TSC22D4 and a vector encoding either the 
control Flag peptide, Flag-TBL1 (A) or Flag-TBLR1 (B). Affinity purification 
was performed with an anti-Flag antibody. Bound proteins were resolved by 
SDS-Page and subsequently detected by Western blot. IN: Input; EL: Elution. 
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5.1.3. TSC22D4 interacts directly with the TBL1 / TBLR1 WD40 domains 
 
Both LUMIER assays and Flag co-immunoprecipitation studies do not clearly 
distinguish between direct and indirect protein-protein interactions. As experiments 
are performed in the presence of all proteins expressed in the cell line of choice, it 
cannot be excluded that specific cellular proteins are required to link the identified 
novel interaction partners. GST-pull down assays were carried out to investigate 
whether the interaction between TSC22D4, TBL1 and TBLR1 is of direct nature, or if 
further components are required for their association. These experiments are 
performed in vitro, meaning that further cellular proteins are not present in the 
reaction mix and only direct interactions can be detected. One protein partner is 
fused to a GST-tag, expressed in bacteria and affinity purified using a glutathione 
matrix. The other protein of interest is in vitro transcribed and translated in the 
presence of 35S-radiolabeled methionine. The two proteins are subsequently 
incubated together. After purification on a glutathione matrix via the GST-tag, it is 
possible to detect the radiolabeled protein by autoradiography, if the proteins directly 
interact and co-precipitate. 
 
First, the GST-peptide alone (negative control), GST-tagged full length TBL1 and the 
TBL1 LisH, F-Box and WD40 domains were incubated with radiolabeled full-length 
TSC22D4. Whilst no signal could be detected in the negative control lane, full-length 
GST-TBL1 did pull-down TSC22D4. This was also the case for the WD40 domain, but 
not the isolated LisH or F-Box domains (Fig. 13).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: TSC22D4 interacts directly 
with TBL1 and TBLR1. GST-pulldown 
assays were performed with full length or 
truncated versions of TSC22D4, TBL1 or 
TBLR1 fused to GST and GST alone as 
a negative control. GST fusion proteins 
were incubated with radiolabeled in vitro 
translated full length TBL1, TBLR1 or 
TSC22D4 protein. Bound proteins were 
resolved by SDS-Page and visualized by 
autoradiography. Input lanes represent 
20% of the input. IN: Input. 
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In order to map the interaction in more detail, the experiment was then performed in 
reverse orientation. GST-tagged TSC22D4, or GST-tagged deletion constructs, 
consisting of the N-terminal 105, 207 or 320 amino acids were incubated with 35S-
radiolabeled full-length TBL1. No signal was detected in the negative control assay, in 
which TBL1 was incubated with the GST peptide alone. As expected, full-length GST- 
TSC22D4 successfully pulled down full-length radiolabeled TBL1. When TBL1 was 
incubated solely with the N-terminal 105 amino acids of TSC22D4, no interaction was 
observed, whilst the longer deletion constructs were sufficient to precipitate the 
interaction partner (Fig. 13), indicating that the sequence between amino acids 105 
and 207 is crucial for the interaction to take place. 
  
To asses if TBLR1 also directly interacts with TSC22D4, or if TBL1 may act as an 
intracellular bridging protein, we incubated radiolabeled TBLR1 with full-length 
GST-TSC22D4 or one of the three TSC22D4 deletion constructs. Again, we observed 
that the full-length proteins interacted and that the TSC22D4 domain ranging from 
amino acids 105 to 207 was required for the effective interaction (Fig. 13). The 
TSC22D4 N-terminus alone did not suffice. 
 
In summary, these data demonstrate a direct interaction between the TBL1 / TBLR1 
C-terminal WD40 domains and the TSC22D4 mid-domain (amino acids 105 to 207) 
(Fig. 14). As both TBL1 and TBLR1 are known to play important roles in liver 
metabolism (63), we decided to further investigate the functional relevance of their 
novel interaction partner, TSC22D4, in regard to its potential involvement in the 
pathogenesis of, or protection against, metabolic disorders. 
 
 
 
 
 
 
 
 
 
Fig. 14: Mapping the interaction between 
TSC22D4, TBL1 and TBLR1. Model of the direct 
interaction between the mid-domain of TSC22D4, 
ranging from amino acids 105 to 207 and the 
TBL1 / TBLR1 WD40 domain. 
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5.2 Analysis of hepatic TSC22D4 expression in mouse 
disease models 
 
 
5.2.1. TSC22D4 is expressed ubiquitously throughout the mouse body 
 
In order to investigate the expression of TSC22D4, TBL1 and TBLR1 throughout the 
body, we analyzed the presence of all three proteins in various mouse tissues by 
Western blot. This analysis served as a reference when deciding which organ to focus 
on in future in vivo experiments. TSC22D4 was expressed in all tissues analyzed, 
albeit at varying levels (Fig. 15 panel 1). Expression was particularly high in the liver 
and inguinal fat, both important tissues for the regulation of energy metabolism.  
 
TBL1 and TBLR1 were however not present in all organs. Interestingly, in some 
tissues both proteins were mutually expressed, whilst only one of the highly related 
proteins seemed to be translated in others, indicating that the two genes are not 
functionally redundant, but have tissue specific functions. Concerning metabolically 
important organs, TBL1 was expressed to a higher extent in liver, pancreas and 
brown adipose tissue (BAT), whilst in abdominal fat TBLR1 was almost exclusively 
expressed (Fig. 15 panel 2, 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Tissue specific expression of TSC22D4, TBL1 and TBLR1. 
Protein lysates from mouse liver, spleen, intestine, heart, lung, pancreas, 
kidney, brain, testis, brown adipose tissue (BAT), inguinal fat, abdominal fat, 
gastrognemius muscle (GC) and stomach were assessed in regard to 
TSC22D4, TBL1 and TBLR1 expression. Proteins were separated by SDS-
Page and subsequently detected by Western blot using TSC22D4, TBL1 and 
TBLR1 antibodies 
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As TSC22D4 is highly expressed in the liver and its novel interaction partners TBL1 
and TBLR1 have been shown to be deregulated in diabetic and pre-diabetic settings 
(63), liver samples taken from mouse models of metabolic stress and disease 
conditions were assessed in regard to TSC22D4 expression. 
 
5.2.2. TSC22D4 expression is not changed upon fasting  
 
During fasting, blood sugar levels fall, insulin secretion by the pancreas is inhibited 
and the pancreatic alpha cells, which are located in the islets of Langerhans, produce 
the hormone glucagon to maintain normoglycemia. Glucagon can bind to hepatocytes 
via the glucagon receptor and stimulate glycogen breakdown (glycogenolysis), glucose 
production (gluconeogenesis) and consequently glucose release from the liver. Upon 
feeding, external glucose is made available and subsequently pancreatic glucagon 
release is suppressed, whilst insulin secretion is induced. In obesity, this tightly 
regulated circuit is impaired and glucose is also released from the liver in the fed 
state, leading to hyperglycaemia (14).  
 
To test if TSC22D4 expression is regulated in response to nutritional restriction, mice 
were fasted for 24 hours. After starvation, one group of animals was sacrificed 
immediately and the other mice were fed for 6 hours. Hepatic TSC22D4 mRNA 
expression was determined by quantitative PCR (Fig. 16). There was no change in 
TSC22D4 mRNA levels in response to fasting or refeeding, indicating that food 
restriction does not act as a signal controlling the expression.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: TSC22D4 expression is not regulated 
by fasting. RNA was extracted from the livers of 
mice fasted for 24 hours and either directly 
sacrificed, or refed for 6 hours after fasting. 
(n=6), (means ± SEM). 
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5.2.3. TSC22D4 expression is not changed in the New Zealand Obese 
mouse model 
 
Mouse models of obesity and type 2 diabetes are commonly used to investigate the 
relevance of specific genes and external factors in metabolism. The New Zealand 
Obese (NZO) mouse represents a polygenic model of diabetes. The strain originally 
resulted from spontaneous mutations during breeding of lean New Zealand Black 
(NZB) mice. As several genes are responsible for the diabetic phenotype displayed by 
these animals, they model the development of the Metabolic Syndrome in humans 
very well. The mice are characterized by a high birth weight, glucose intolerance and 
hypertension (67). To asses if TSC22D4 expression is influenced by the obese 
phenotype, hepatic RNA was isolated and the abundance of TSC22D4 mRNA was 
assessed. A difference in TSC22D4 expression could not be detected (Fig. 17). 
 
 
 
 
 
 
 
 
 
 
5.2.4. TSC22D4 expression is reduced in leptin deficient mice 
 
In the fed state, the hormone leptin is secreted by adipocytes and transported to the 
hypothalamus via the blood stream. In the brain, it serves as a neuroendocrine signal 
for satiety and leads to appetite suppression. Furthermore, leptin regulates the 
metabolic rate via central mechanisms. Homozygous loss of function mutations in the 
leptin gene as observed in ob/ob mice (Lepob), lead to hyperphagia, hyperglycaemia, 
hyperinsulinemia and subsequently severe obesity and pre-diabetes (68).  TSC22D4 
gene expression was analyzed in random fed ob/ob and control wild type mice. 
mRNA levels were significantly (~40%) reduced in the ob/ob mice compared to the 
Fig. 17: TSC22D4 expression is not changed in 
New Zealand Obese mice. RNA was extracted 
from the livers of lean New Zealand Black (NZB) 
and diabetic New Zealand Obese (NZO) mice. 
TSC22D4 expression was subsequently determined 
by quantitative PCR. (n=6), (means ± SEM). 
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wild type controls, indicating that TSC22D4 could be linked to the onset of obesity 
(Fig. 18).  
 
 
 
 
 
 
 
 
 
 
5.2.5. TSC22D4 expression is reduced in high fat diet fed mice 
 
The majority of type 2 diabetes cases in the human population result from reduced 
energy expenditure and excessive caloric intake, as associated with a sedentary 
lifestyle and a diet rich in fat and sucrose. The consumption of excess fat thereby 
leads to increased fat accumulation throughout the body. Fat is stored in adipose 
tissue and ectopically in organs, such as the liver, leading to tissue damage. Over 
time, obese individuals develop glucose intolerance and ultimately type 2 diabetes 
mellitus (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: TSC22D4 expression is reduced in leptin 
deficient ob/ob mice. RNA was extracted from the 
livers of lean control and obese ob/ob mice. 
TSC22D4 expression was subsequently determined 
by quantitative PCR. (n=4), (means ± SEM). (*) 
indicates significance; p < 0.05. 
 
Fig. 19: TSC22D4 expression is reduced in mice upon a high fat diet. Mice were 
fed a control low fat diet (LFD) or a high fat diet (HFD). Their weight was determined 
after 9 weeks on the respective diet (A). RNA was extracted from the livers of these 
mice and TSC22D4 expression was subsequently determined by quantitative PCR (B); 
(n=4), (means ± SEM). (*) indicates significance; p < 0.05. 
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The onset of obesity can be modelled by feeding mice a high fat diet over the course of 
several weeks. On such a diet, the animals gain weight quickly and develop 
hyperglycaemia, hyperinsulinemia and hypertension (69). TG content increases in 
the adipose tissue, blood and liver whilst energy expenditure and activity decrease. To 
assess the consequences concerning TSC22D4 expression, mice were fed either a high 
fat diet containing 60% energy from fat or a control low fat diet containing 10% 
energy from fat over a 9 week period. The mice consuming the high fat diet put on 
significantly more weight (Fig. 19 A) and developed hyperglycaemia (data not 
shown). Hepatic TSC22D4 expression levels were determined after the mice had been 
sacrificed (Fig. 19 B). TSC22D4 expression was significantly (~60%) lower in mice fed 
the high fat diet, further strengthening the notion that TSC22D4 may be involved in 
the development of obesity and the Metabolic Syndrome. 
  
Consistent with the elevation of counter-regulatory hormonal pathways in insulin 
resistance, particularly adrenal glucocorticoids (14), chronic exposure of wild-type 
mice to the anti-inflammatory synthetic steroid dexamethasone for 3 weeks also 
triggered the inhibition of TSC22D4 mRNA levels (Fig. 20). Glucocorticoids stimulate 
gluconeogenesis in the liver by binding to the glucocorticoid receptor. Due to their 
anti-inflammatory properties they are often used as medication to treat inflammatory 
conditions. A side effect of chronic exposure is however the development of diabetes 
and hypertension, as they induce an elevation of blood glucose levels (70,71). 
 
 
 
 
 
 
 
 
 
Taken together, these results suggest that hepatic TSC22D4 is specifically down-
regulated in metabolic stress conditions, as associated with insulin resistant obesity. 
To further address the role of TSC22D4 in this context, functional experiments 
Fig. 20: TSC22D4 expression is reduced in 
glucocorticoid treated mice. RNA was extracted from 
the livers of mice injected with 1.2 mg/kg 
dexamethasone (Dex) intrapertioneally every day for 3 
weeks. Control mice received an equal volume saline. 
TSC22D4 expression was subsequently determined by 
quantitative PCR. (n=4), (means ± SEM). (*) indicates 
significance; p < 0.05. 
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needed to be performed in which TSC22D4 expression was artificially decreased or 
enforced in the livers of wild type mice. 
 
 
5.3 Hepatic TSC22D4 knock down leads to elevated serum 
triglyceride levels in C57BL/6J mice 
 
 
Adenoviral vectors are commonly used to genetically manipulate mammalian cells, or 
whole organs. Vectors expressing short hairpin RNAs (shRNA) targeting specific 
sequences for degradation by the RNA induced silencing complex (RISC) are easy to 
generate and it is possible to produce large titres, ranging up to 1 x 1012 infectious 
units per ml. Several different mammalian cell types can be transduced by adenovirus 
expressing the constitutively active U6-polymerase III promoter. After the shRNA 
transgene has been transcribed, it forms a stem loop structure which is processed by 
the cellular RNA interference (RNAi) machinery. During this process, the loop 
structure is removed and a mature RNAi construct is produced (72). Tail vein 
injection of adenovirus into mice largely results in the infection of liver cells, as the 
virus is transported directly to the liver’s capillary system. This approach has the 
advantage that liver specific gene function can be investigated, as other tissues are 
hardly affected by the transgene. Experiments using adenovirus need to be performed 
in a specific time window, as the viral genes (especially E2 and E4) expressed after 
infection lead to an immune response that clears the vector after approximately 14 
days. The ideal time point for phenotypic analysis has been shown to be 7 days post 
infection (71). 
 
5.3.1. Liver specific TSC22D4 knock down using RNA interference 
 
Specific shRNA sequences targeting TSC22D4 were cloned into the Invitrogen 
pENTR-DEST vector. Their knock down efficiency was tested by co-transfecting Hepa 
1c1 cells with the shRNAs and a TSC22D4 over expression construct. TSC22D4 
depletion was then analyzed by Western blot (data not shown). The most promising 
sequence was sub-cloned into the second generation Invitrogen pAD-BLOCK-IT 
vector. The vector contained the majority of the viral genome, but lacked the E1 and 
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E3 genes required for viral replication (safety feature). Virus was produced by 
transfecting HEK293A cells, which expressed the missing genes in trans. The 
resulting replication incompetent adenovirus was purified using the caesium chloride 
method (71). In order to investigate the effects of reduced TSC22D4 expression in the 
livers of C57BL/6J mice, 1 x 109 viral particles expressing either a scrambled shRNA 
sequence (control), or the sequence targeting the TSC22D4 mRNA were administered 
via the tail vein. Mice were given free access to food and considered random fed. 
Seven days after injection the animals were sacrificed. Liver, gastrocnemius muscle, 
kidney and inguinal fat were collected and shock frozen. TSC22D4 knock down 
efficiency was assessed at RNA level by quantitative PCR and at protein level by 
Western blot. RNA levels were reduced by approximately 60% (Fig. 21 A). TSC22D4 
protein levels (Fig. 21 B) were also significantly lower in the TSC22D4 knock down 
group than in the control shRNA treated subgroup. To test the tissue specificity of the 
knock down, TSC22D4 protein expression was also assessed in skeletal muscle and 
kidney. Expression remained unaffected in both organs (Fig. 21 B). As the viral 
construct had effectively knocked down TSC22D4, the mice were subsequently 
thoroughly analyzed in regard to the resulting phenotype. Systemic, as well as, organ 
specific effects on glucose and lipid metabolism were thereby investigated. 
 
 
 
 
 
 
   
Fig. 21: shRNA mediated knock down of TSC22D4 mRNA and protein. Quantitative PCR 
analysis of liver RNA extracts from representative control or TSC22D4 shRNA adenovirus–
injected C57BL/6J mice 7 days after injection (A). Western blot of liver, gastrocnemius skeletal 
muscle (SkM) and kidney extracts from representative control (lanes 1-3) or TSC22D4 (lanes 4-6) 
shRNA adenovirus–injected C57BL/6J mice 7 days after injection using TSC22D4 and VCP 
antibodies (B); (n>7), (means ± SEM). (*) indicates significance; p < 0.05. 
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5.3.2. Phenotypic analysis of TSC22D4 deficient C57BL/6J mice 
 
5.3.2.1. Body weight, liver weight, body fat and lean mass 
 
To asses if TSC22D4 deficiency acutely affects total body weight or fat distribution, 
mice were weighed before the sacrifice. Furthermore, their body composition was 
assessed using an Echo MRI body composition analyzer. This device is capable of 
determining total fat mass, as well as lean mass, consisting of mainly muscles, 
tendons and connective tissues. No changes in either body weight (Fig. 22 A), fat 
mass (Fig. 22 C), or lean tissue mass (Fig. 22 D) were measureable 7 days after 
TSC22D4 shRNA delivery. Liver weight, as determined during preparation of the 
mice also remained unchanged by TSC22D4 knock down (Fig. 22 B). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
5.3.2.2. Hepatic glycogen and circulating glucose, insulin and ketone bodies 
 
After consuming food, glucose is taken up into the blood stream and serves as an 
energy source for the brain. Excess glucose is however stored in the liver, where it is 
converted to the starch like polymer glycogen. At times in which dietary energy is not 
available, for example during sleep periods, these stores are utilized to maintain 
normoglycemia and guarantee energy availability to the brain. This balance in 
glucose metabolism is tightly regulated by insulin (14). In order to investigate the role 
Fig. 22: Body weight and 
composition are not 
affected by hepatic 
TSC22D4 knock down. 
Body weight (A), liver weight 
(B), fat (C) and lean (D) 
mass of mice treated with 
control or TSC22D4 shRNA 
adenovirus were determined 
6-7 days after infection; 
(n>7), (means ± SEM). 
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of TSC22D4 in glucose metabolism, blood glucose levels and hepatic glycogen stores 
were analyzed. Whilst blood glucose remained unaffected (Fig. 23 A), a slight 
increase in glycogen content was measured in random fed TSC22D4 deficient mice 
(Fig. 23 B). In line with this observation, serum insulin levels were slightly, albeit not 
significantly, elevated (Fig. 23 D). 
 
Energy deficiency in the brain has severe consequences for the whole body and 
keeping this organ nourished is of highest priority. If, during prolonged fasting, blood 
glucose levels are not sufficient to supply the brain with energy, ketone bodies serve 
as an alternative energy source. These substances are produced by the liver and are 
by-products of beta oxidation (fatty acid breakdown). Acetyl-CoA serves as the 
substrate and the process is known as ketogenesis. In the brain, ketone bodies are 
broken down to acetyl-CoA and fed into the citric acid cycle to produce energy (73). 
Levels of circulating ketone bodies remained unaffected by TSC22D4 knock down 
(Fig. 23 D). In conclusion, these results show that glucose metabolism was not 
significantly affected by TSC22D4 depletion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Glucose, glycogen 
insulin and ketone body 
levels upon TSC22D4 
knock down. Blood glucose 
(A), hepatic glycogen (B), 
serum insulin (C) and 
ketone bodies (D) were 
determined in mice treated 
with control or TSC22D4 
shRNA adenovirus 7 days 
after injection; (n>7), 
(means ± SEM). * indicates 
significance; p < 0.05. 
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5.3.2.3. Hepatic and serum lipids and steroids 
 
After sacrificing the mice, lipids were isolated from the livers in order to investigate 
the effects of TSC22D4 on lipid and steroid metabolism. Non-esterified free fatty 
acids (NEFA) are imported into the liver via lipoprotein particles, esterified and used 
for the production of TGs and as a substrate for beta oxidation (74). Hepatic and 
serum NEFA levels were determined using a commercial kit.  Whilst a mild decrease 
was observed in the liver (Fig. 24 A), serum NEFA levels were unaffected by 
TSC22D4 knock down (Fig. 24 B). 
 
 
 
 
 
 
 
 
 
 
 
 
Cholesterol is a steroid that is produced by the liver and subsequently transported 
throughout the periphery by lipoprotein particles. It is an important component of 
cellular membranes and also a necessary substrate for the production of hormones 
and bile acids. Elevated cholesterol levels are however associated with metabolic 
complications, such as atherosclerosis and cardiovascular disease (75). Hepatic and 
serum cholesterol content were determined using a commercial kit. Whilst TSC22D4 
knock down did not change liver cholesterol content (Fig. 25 A), circulating 
cholesterol was slightly, but significantly, elevated, hinting towards an involvement of 
TSC22D4 in the metabolism of lipoprotein particles (Fig. 25 B).  
Fig. 24: Liver non-esterified fatty acids are slightly reduced upon TSC22D4 
knock down. Liver (A) and total serum (B) non-esterified fatty acid (NEFA) content 
was determined from mice treated with control or TSC22D4 shRNA adenovirus 7 days 
after infection; (n>7), (means ± SEM). (*) indicates significance; p < 0.05. 
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TGs are either taken up by the intestine or produced by and stored in the liver. When 
required, they are released from the liver and transported throughout the body by 
lipoprotein particles, providing energy to adipose and muscle tissue. Elevated TG 
levels in the liver (hepatic steatosis), as associated with the Metabolic Syndrome, lead 
to liver fibrosis and ultimately cancer. Excessive blood TG levels 
(hypertriglyceridemia) are associated with cardiovascular diseases (27,76). To asses if 
TG trafficking is deregulated in the absence of TSC22D4, hepatic and serum TG levels 
were determined using a commercial kit. Whilst hepatic TG stores were significantly 
decreased by TSC22D4 knock down (Fig. 26 A), serum TGs were markedly elevated 
more than 2-fold (Fig. 26 B), indicating disrupted TG trafficking either to or from the 
liver.  
 
 
 
 
Fig. 25: Serum, but not hepatic cholesterol levels are elevated upon TSC22D4 knock 
down. Liver (A) and total serum (B) cholesterol content was determined from mice treated 
with control or TSC22D4 shRNA adenovirus 7 days after infection; (n>7), (means ± SEM). 
(*) indicates significance; p < 0.05. 
 
Fig. 26: Hepatic triglycerides are reduced, whilst serum triglycerides are elevated upon 
TSC22D4 knock down. Liver (A) and total serum (B) triglyceride (TG) content was 
determined from mice treated with control or TSC22D4 shRNA adenovirus 7 days after 
infection; (n>7), (means ± SEM). (*) indicates significance; p < 0.05. 
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5.3.3. TSC22D4 deficient mice display elevated circulating VLDL 
triglycerides 
 
Generally TGs are released by the liver and transported as components of multi-
protein complexes known as very low density lipoprotein (VLDL) particles. Elevated 
VLDL levels are associated with increased risk of diabetes, cardiovascular diseases, 
heart attacks and strokes and contribute significantly to the Metabolic Syndrome 
(36). As an increase in serum TG levels was observed in mice after TSC22D4 knock 
down, we analyzed the different lipoprotein species in regard to their TG and 
cholesterol content. To this effect, total serum was fractionated by size exclusion 
using fast protein liquid chromatography and a Superose 6 10/300 GL column. As 
larger particles migrate through the matrix quicker than denser ones, it is possible to 
separate the lipoproteins according to size. VLDL particles are collected first, 
followed by low density (LDL) and finally high density (HDL) lipoprotein particles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27: VLDL triglycerides are 
elevated in TSC22D4 deficient 
mice. Lipoprotein-associated 
serum triglyceride (TG) (A) and 
cholesterol (B) levels as measured 
by fast protein liquid 
chromatography (FPLC). Serum 
from mice treated with either 
control or TSC22D4 shRNA 
adenovirus was pooled 7 days after 
infection and applied to a Superose 
6 10/300 GL column; (n≥7). 
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Indeed, the observed increase in serum TGs could be attributed to the VLDL fraction, 
as the corresponding peak (fraction number 17) was significantly higher (Fig. 27 A) 
than in the control group. Hardly any TGs were measured in the HDL fraction. HDL 
particles mainly transport cholesterol. No clear differences in the lipoprotein profile 
could be seen concerning the distribution of cholesterol within the HDL fraction 
(fraction number 33) upon TSC22D4 knock down (Fig. 27 B). 
 
5.3.4. Hepatic triglyceride levels are deregulated in the fasted state 
 
As mice are nocturnal animals, they primarily consume food in the dark period. 
Therefore, when they are fasted overnight, this represents quite severe starvation and 
leads to considerable metabolic stress. Interestingly, hepatic and serum TG stores are 
significantly elevated in this situation (personal observation). The increased hepatic 
TG content upon fasting is probably due to uptake of more NEFA after their higher 
release from adipose tissue. Subsequently more VLDL may be secreted by the liver in 
an effort to provide the periphery with TGs as a source of energy. The precise 
mechanism underlying this phenomenon is however so far not known. To investigate 
if TSC22D4 plays a role in the fasting, or immediate refeeding response, 12 mice were 
injected with the TSC22D4 or control shRNA adenovirus. Six days after injection, 
their food was withdrawn in the evening. The following morning, six mice were 
sacrificed in the starved state, whilst the other mice were refed for precisely 6 hours 
before they were prepared. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 28: Hepatic 
triglycerides are 
strongly reduced in 
TSC22D4 deficient 
mice. Liver sections from 
representative C57BL/6J 
mice, either fasted for 16 
hours or refed for 6 
hours, 7 days after 
injection of either control 
or TSC22D4 shRNA 
adenovirus. Lipids were 
stained red using Oil Red 
O.  
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Liver sections were stained with Oil Red O, a fat soluble dye that specifically stains 
neutral TGs. As expected, hepatic TGs accumulated in the fasted state in control mice 
and were reduced by feeding. TSC22D4 knock down resulted in a significant decrease 
in liver TG content in both the fasted and refed state. Hardly any TGs were visible in 
refed TSC22D4 deficient mice (Fig. 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The observed decrease in hepatic TG content in both fasted and refed TSC22D4 
knock down animals was also determined by colorimetric assay (Fig. 29 A, B). 
Concerning TG release by the liver, no differences were observed in the already high 
total fasting serum TG levels (Fig. 29 C). Upon refeeding, however, TSC22D4 
deficient mice had significantly higher circulating TGs than their control shRNA 
treated counterparts (Fig. 29 D). In this context, FPLC analysis revealed that this 
elevation can be attributed to an increase in the VLDL peak in fed TSC22D4 deficient 
mice (Fig. 30 A, B).  
Fig. 29: Fasting liver 
triglycerides are reduced 
in TSC22D4 deficient 
mice. Liver triglyceride 
(TG) content was 
determined from 16 hour 
fasted (A) and 6 hour 
refed (B) mice, treated 
with control or TSC22D4 
shRNA adenovirus 7 days 
after infection. Total serum 
TGs were determined in 
the same mice (C, D); 
(n>7), (means ± SEM). (*) 
indicates significance; p < 
0.05. 
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5.3.5. VLDL production is increased upon TSC22D4 knock down 
 
The observed changes in hepatic and serum TG levels could either be due to reduced 
VLDL clearance in the periphery or increased lipogenesis and VLDL secretion by the 
liver. Individual studies were applied to asses these possible mechanisms. 
5.3.5.1. VLDL clearance is not changed upon TSC22D4 knock down 
 
Lipoprotein lipase (LPL) is the enzyme required for VLDL-TG hydrolysis enabling 
uptake of NEFA into muscle and adipose tissue. The protein is mainly expressed in 
white adipose tissue and skeletal muscle, where it is attached to the capillaries. By 
hydrolyzing TGs into three free fatty acids and one monoacylglycerol, LPL provides 
energy (fatty acids) which is either stored in the adipose tissue, or consumed by 
muscle (77). Reduced LPL activity would result in an increased VLDL TG content in 
the blood stream. To investigate if LPL activity was affected by hepatic VLDL knock 
down, the enzyme was isolated from white adipose tissue. A subsequent activity assay 
was performed using radiolabeled glyceryl tri-[14C] oleate. No significant changes 
were observed in LPL activity upon TSC22D4 knock down (Fig. 31 A), indicating that 
this is not the mechanism underlying the observed phenotype. 
 
Excess VLDL particles can be cleared by the liver to prevent accumulation in the 
blood stream. Specific receptors, expressed on the membranes of hepatocytes 
Fig. 30: TSC22D4 knock down elevates circulating VLDL triglyceride levels in the fed, but not 
the fasted state. Lipoprotein-associated serum triglyceride (TG) levels as measured by fast protein 
liquid chromatography (FPLC). Serum from 16 hour fasted (A) or 6 hour refed (B) mice treated with 
either control or TSC22D4 shRNA adenovirus was pooled 7 days after infection and applied to a 
Superose 6 10/300 GL column; (n≥7). 
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mediate this process. To test if this form of clearance was affected by TSC22D4 knock 
down, mice were fasted for 4 hours and injected purified human VLDL via the tail 
vein. Blood was taken at distinct time points and human Apolipoprotein B (ApoB) 
levels in the serum were determined using an enzyme-linked immunosorbent assay 
(ELISA) that specifically recognizes the human and not the murine protein isoform. 
Clearance was slightly improved in TSC22D4 deficient mice as these animals 
removed the human protein from the blood stream quicker (Fig. 31 B). The difference 
was however rather small and could not explain the observed phenotype, as improved 
clearance would prevent, rather than induce, serum hypertriglyceridemia. Possibly, 
VLDL clearance is improved upon TSC22D4 knock down as a compensatory 
mechanism to counteract elevated serum TG levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5.3.5.2. Hepatic VLDL production is enhanced in TSC22D4 deficient mice 
 
A VLDL production assay was performed to address if changes in VLDL release by 
the liver could account for the increase in circulating serum VLDL TG levels in 
TSC22D4 deficient mice. Animals were injected with the non-ionic detergent 
tyloxapol, leading to a complete inhibition of peripheral LPL (78). Subsequently, all 
VLDL particles released by the liver accumulated in the blood stream over time. 
Blood was drawn at specific time points after tyloxapol administration and TG levels 
were determined colorimetrically. Indeed, TSC22D4 knock down led to a significantly 
Fig. 31: TSC22D4 knock down does not reduce VLDL clearance from the blood stream. 
White adipose tissue lipoprotein lipase (LPL) activity was determined in C57BL/6J mice treated 
with control or TSC22D4 shRNA adenovirus (A). Clearance of human ApoB from serum of 
control or TSC22D4 shRNA adenovirus–injected C57BL/6J mice was determined 7 days after 
injection. 20μg of human VLDL were injected into each animal and serum samples were taken 
at the indicated time points. Human ApoB levels were determined by human-specific ELISA (B); 
(means ± SEM, n>6). 
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increased VLDL secretion rate. Over time, about 25% more VLDL particles were 
released by TSC22D4 deficient mice, which can explain the elevated serum TG levels 
after knock down (Fig. 32 A). 
  
ApoB is the main protein component of VLDL particles (33). If VLDL secretion is 
amplified, subsequently, more ApoB protein is required for VLDL assembly. To 
investigate if hepatic ApoB levels were affected by TSC22D4 knock down, Western 
blots were performed using liver protein lysates from control and TSC22D4 deficient 
mice. Increased ApoB protein levels were observed in mice after TSC22D4 knock 
down, further strengthening the hypothesis that VLDL production is induced in the 
absence of TSC22D4 (Fig. 32 B).  
 
 
 
 
5.3.5.3. Lipogenic gene expression is induced in TSC22D4 deficient mice 
 
As serum VLDL levels were elevated in TSC22D4 deficient mice, it was likely that TG 
biosynthesis in the liver (lipogenesis) was increased to account for the higher 
requirements. Quantitative real time PCR was used to investigate the expression of 
key lipogenic genes using cDNA produced from hepatic RNA extracts. The 
investigated genes and a short description of their hepatic function are listed in Tab. 
2.  
 
Fig. 32: TSC22D4 knock down leads to increased VLDL secretion by the liver. Hepatic very-
low-density lipoprotein (VLDL) release in control or TSC22D4 shRNA adenovirus injected wild-type 
C57BL/6J mice 7 days after injection. Time after tyloxapol injection indicated (A). Hepatic 
apolipoprotein B (ApoB) protein levels in representative control or TSC22D4 shRNA adenovirus–
injected C57BL/6J mice were determined by Western blot 7 days after injection using ApoB and 
VCP antibodies (B); (n=6), (means ± SEM). (*) indicates significance; p < 0.05. 
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All lipogenic genes analyzed were strongly up-regulated in livers of random fed 
C57BL/6J mice lacking TSC22D4, indicating that not only VLDL release, but also ne-
novo TG biosynthesis and VLDL production were enhanced (Fig. 33). 
 
 
 
 
 
 
 
 
 
 
 
To investigate if other metabolic processes in the liver were affected by TSC22D4 
knock down, the expression of genes involved in bile acid metabolism [src-homology 
protein 1 (Shp1), cholesterol 7 alpha-hydroxylase (Cyp7a1)], VLDL clearance 
[receptor-related protein (Lrp), low-density lipoprotein receptor (Ldlr), lipolysis 
stimulated lipoprotein receptor (Lsr)] and lipoprotein inhibition [apolipoprotein C 1 
(Apoc1), apolipoprotein C 2 (Apoc2), apolipoprotein A 1 (Apoa1), angiopoietin-like 3 
(Angptl3), angiopoietin-like 4 (Angptl4)] was assessed (Fig. 34 A-B). No significant 
changes in the expression of these genes were observed, indicating that the effects on 
gene expression were specific to lipogenesis. 
 
Gene name Abbreviation Function 
ATP-citrate lyase Acly Acetyl CoA synthesis 
Acetyl-CoA carboxylase Acc1 Conversion of acetyl CoA to malonyl CoA 
Fatty acid synthase Fasn Fatty acid elongation 
Stearoyl-CoA desaturase-1 Scd1 Production of desaturated fatty acids 
Sterol regulatory element-
binding protein 1 
Srebp1 Transcription factor regulating lipogenic gene 
expression 
Lipin1 Lipin1 Involved in VLDL production 
Peroxisome proliferator-
activated receptor alpha 
Ppara Transcription factor regulating hepatic lipid 
metabolism 
Tab. 2: List of analyzed genes involved in hepatic lipid metabolism and lipogenesis. 
Fig. 33: Expression of lipogenic 
genes is upregulated in TSC22D4 
deficient mice. Quantitative PCR 
analysis of ATP citrate lyase (Acly), 
acetyl-coenzyme A carboxylase 1 
(Acc1), fatty acid synthase (Fasn), 
stearoyl-CoA desaturase-1 (Scd1), 
sterol regulatory element-binding 
protein-1c (Srebp1), Lipin1 and  
peroxisome proliferator-activated 
receptor α (Ppara) mRNA levels in  
livers of control or TSC22D4 shRNA 
adenovirus-injected wild-type 
C57BL/6J mice 7 days after injection; 
(n>7), (means ± SEM). (*) indicates 
significance; p < 0.05. 
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The liver not only contains hepatocytes, but also several other cell types, including 
quiescent pericytes (stellate cells) immune reactive macrophages (Kupffer cells), 
fibroblasts, and blood cells. To assure that the observed effects on lipogenic gene 
expression were hepatocyte specific, primary hepatocytes were isolated from 
C57BL/6J mice and cultivated in vitro. The isolated hepatocytes were then 
transduced using adenovirus expressing either control, or TSC22D4 shRNA. 
Lipogenic gene expression was analyzed. Several lipogenic genes, including Acly, Scd1 
and Ppara were also up regulated in this ex-vivo setting (Fig. 35), indicating that 
TSC22D4 knock down induces lipogenic gene expression in hepatocytes in a cell-
autonomous manner. 
 
 
 
 
 
 
 
 
 
Fig. 35: Lipogenic genes are upregulated in 
TSC22D4 deficient primary mouse hepatocytes. 
Quantitative PCR analysis of TSC22D4, ATP citrate 
lyase (Acly), stearoyl-CoA desaturase-1 (Scd1), 
peroxisome proliferator-activated receptor α (Ppara) 
mRNA levels in  primary (1°) mouse hepatocytes 
treated with control or TSC22D4 shRNA adenovirus; 
(n=3), (means ± SEM). (*) indicates significance; p < 
0.05. 
Fig. 34: Expression of genes involved in bile acid metabolism, VLDL clearance and 
lipoprotein processing is not affected by TSC22D4 knock down. Quantitative PCR analysis of 
src-homology protein 1 (Shp1), cholesterol 7 alpha-hydroxylase (Cyp7a1), lipoprotein receptor-
related protein (Lrp), low-density lipoprotein receptor (Ldlr) and lipolysis stimulated lipoprotein 
receptor (Lsr) mRNA levels in livers of control or TSC22D4 shRNA-injected wild-type C57Bl6 mice 
(A). Quantitative PCR analysis of apolipoprotein C 1 (Apoc1), apolipoprotein C 2 (Apoc2), 
apolipoprotein A 1 (Apoa1), angiopoietin-like 3 (Angptl3), angiopoietin-like 4 (Angptl4) mRNA levels 
in livers of control or TSC22D4 shRNA-injected wild-type C57BL/6J mice (B); (n>7), (means ± SEM). 
(*) indicates significance; p < 0.05. 
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5.3.6. Whole genome expression profiling in TSC22D4 deficient mice 
 
To further investigate the consequences of TSC22D4 deficiency concerning hepatic 
gene expression, microarray analysis was performed using RNA extracts isolated 
from the livers of random fed control or TSC22D4 deficient mice. The up regulation 
of the lipogenic genes shown in Fig. 33 was confirmed in this experiment (data not 
shown). Pathway analysis revealed that biosynthesis of steroids, fatty acid 
metabolism, fatty acid elongation, adipokine signalling, PPAR signalling, the citrate  
cycle (tricarboxylic acid cycle) and fatty acid biosynthesis were amongst the pathways 
which were regulated the strongest in TSC22D4 deficient mice (Fig. 36 A). These 
results are in line with the observed elevation of serum TGs. 
 
 
 
 
 
 
 
The increase in serum TGs and the induction of lipogenesis seen after TSC22D4 
knock down had also been described in TBL1 and TBLR1 double deficient mice (63). 
Fig. 36: Hepatic pathway expression analysis of TSC22D4 or TBL1 / TBLR1 deficient livers. 
Significantly regulated pathways upon hepatic TSC22D4 knock down, as determined by Affymetrix 
microarray analysis (A). Venn diagram displaying the overlap of significantly regulated genes upon 
TSC22D4 and TBL1 / TBLR1 knock down (B). Western blot of liver, extracts from representative 
control or TSC22D4 shRNA adenovirus–injected C57BL/6J mice 7 days after injection using Lipin1, 
Acly and VCP antibodies (C). Western blot of liver, extracts from representative control or TBL1 and 
TBLR1 shRNA adenovirus–injected C57BL/6J mice 7 days after injection using Lipin1, Acly and VCP 
antibodies (D). P < 0.05. 
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Microarrays were performed using liver RNA extracts from these TBL1 / TBLR 
deficient animals. When comparing the genes regulated by either TSC22D4 or TBL1 / 
TBLR1 knock down, it was evident that a large portion of the regulated genes 
overlapped, whilst other genes were only significantly regulated in one of the two 
experimental settings (Fig. 36 B). This fits with the fact that the absence of TSC22D4 
only in part copies the phenotype observed after hepatic TBL1 / TBLR1 double knock 
down. Both groups of mice display increased lipogenesis, but TSC22D4 deficient mice 
have reduced hepatic TG stores, whilst TBL1 / TBLR1 knock down animals have 
highly steatotic livers. It has furthermore been shown that TG secretion is not 
changed in TBL1 / TBLR1 deficient animals (63). 
 
Western blot analyses of Acly and Lipin1 protein expression were performed using 
hepatic protein extracts from random fed TSC22D4 or TBL1 / TBLR1 deficient mice. 
Acly, a gene primarily involved in lipogenesis was, as expected, up regulated in both 
settings. Lipin1, a gene required for VLDL release, was however only up regulated 
upon TSC22D4 knock down. (Fig. 36 C, D). These results emphasize that TSC22D4, 
TBL1 and TBLR1 only in part have directly overlapping functions, primarily 
concerning lipogenesis. 
 
5.3.7. Acute TSC22D4 knock down affects insulin signalling, but not 
glucose or insulin tolerance 
 
In both humans and mice, over time, increased circulating TG levels are known to 
cause insulin resistance and ultimately contribute to the development of type 2 
diabetes (79). As shRNA mediated knock down of TSC22D4 led to a marked increase 
in serum TG levels, we decided to investigate the consequences of the resulting 
hypertriglyceridemia in regard to glucose tolerance and insulin sensitivity.  
 
Mice were injected with adenovirus expressing the control or TSC22D4 specific 
shRNA. One week after injection, an intravenous glucose tolerance test (GTT) was 
performed to investigate if the capacity to handle glucose was altered by TSC22D4 
knock down. For this cause, a bolus of glucose (10 µl of a 20% solution / g mouse 
weight) was injected intraperitoneally and blood sugar levels were monitored over 
time. No differences could be observed in clearance of the externally infused glucose, 
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indicating that glucose tolerance is not acutely affected by short-term TSC22D4 
deficiency (Fig. 37 A).  
 
In a second experiment, an intravenous insulin tolerance test (ITT) was performed to 
address the effects regarding insulin sensitivity. After insulin administration, blood 
glucose levels quickly decreased in both the control and the TSC22D4 knock down 
group. They then recovered within 2 hours. No major differences were observed 
between the TSC22D4 deficient and the control mice, indicating that insulin 
tolerance was also not acutely affected (Fig. 37 B). 
 
 
 
 
One week of TSC22D4 deficiency had not sufficed to induce systemic glucose 
intolerance, or insulin resistance. We therefore investigated the sensitivity of the 
insulin signalling cascade at the molecular level. Control or TSC22D4 deficient mice 
were injected either PBS, or 1U/kg insulin and prepared precisely 10 min after 
injection. Hepatic insulin signalling was subsequently assessed by analysing protein 
kinase B (PKB=AKT) and glycogen synthase kinase 3 (GSK3) activity, as determined 
by their phosphorylation status.  
 
No differences could be seen in the basal, non-stimulated state. The insulin induced 
phosphorylation of both AKT and GSK3 was, however, blunted in TSC22D4 deficient 
mice, representing the first step in the development of insulin resistance in these 
Fig. 37: Glucose tolerance and insulin sensitivity are not affected by TSC22D4 knock down. 
Glucose tolerance test (GTT) (A) and insulin tolerance test (ITT) (B) in control or TSC22D4 shRNA 
adenovirus–injected C57BL/6J mice 7 days after injection; (means ± SEM). P < 0.05, * indicates 
significance. 
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animals (Fig. 38). It is plausible that over time, this defect in insulin sensitivity could 
favour the development of systemic insulin resistance and the Metabolic Syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.8. TSC22D4, TBL1 and TBLR1 triple deficiency leads to severe 
hypertriglyceridemia 
 
TSC22D4 has been shown to directly physically interact with TBL1 and TBLR1. On 
the one hand, the absence of each one of the three proteins alone induces significant 
hypertriglyceridemia. In contrast however, TBL1 and TBLR1 deficiency favour liver 
steatosis, whilst TSC22D4 knock down reduces hepatic TG stores. The question 
therefore arose, as to the consequences of TSC22D4, TBL1 and TBLR1 triple 
deficiency.  To address this point, we acutely knocked down either, TSC22D4 alone, 
TBL1 and TBLR1 in combination, or all three genes at once using 1x 109 infectious 
units of each virus. In all cases the total titre was adjusted to 3x 109 using adenovirus 
expressing the control shRNA. Mice injected with control virus served as one control, 
whilst a second control group consisted of mice injected PBS instead of adenovirus. 
Fig. 38: Insulin signaling is blunted in TSC22D4 
deficient mice. Western blot of liver extracts from 
representative control or TSC22D4 shRNA adenovirus-
injected C57BL/6J mice 7 days after injection using AKT 
(AKT=PKB, Protein Kinase B), phospho AKT (pAKT), 
GSK3 (Glycogen Synthase Kinase 3), phospho GSK3 
(pGSK3) and VCP antibodies. Animals were either 
injected with PBS or 1U/kg body weight insulin 10 min 
prior to sacrifice. Mice were analyzed in the fed state 
(n=3). 
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Knock down efficiency was not as strong as in past experiments (Fig. 39 A). 
Nevertheless, the severe hepatic steatosis associated with TBL1 / TBLR1 double 
knock down (63) was observed, but only slightly reduced by additional TSC22D4 
deficiency (Fig. 39 B). Serum hypertriglyceridemia was seen upon TSC22D4 single 
knock down and TBL1 / TBLR1 double knock down. Serum TG levels were even 
further increased in the TSC22D4, TBL1, TBLR1 triple deficient mice (Fig. 39 C). 
Although the consequences did not seem additive, TSC22D4 / TBL1 / TBLR1 triple 
knock down did have very severe effects on circulating TG levels. No differences were 
observed between the control virus injected mice and PBS treated mice, indicating 
that the observed phenotypes did not result from off-target viral effects. 
 
 
 
 
Fig. 39: TSC22D4, TBL1 and TBLR1 triple deficient mice have elevated serum and liver 
triglycerides. Western blot of liver extracts from fed representative control, TSC22D4, TBL1 and 
TBLR1 or TSC22D4, TBL1, TBLR1 shRNA adenovirus–injected C57BL/6J mice 7 days after injection 
using TSC22D4, TBL1, TBLR1 and VCP antibodies (A). Liver (B) and serum (C) triglyceride (TG) 
content in the same mice as in a; (means ± SEM, n ≥ 6). P < 0.05, * indicates significance. 
Fig. 40: TSC22D4, TBL1 and TBLR1 triple deficient mice have elevated VLDL triglycerides. 
Lipoprotein-associated serum triglyceride (TG) (A) and cholesterol (B) levels as measured by fast 
protein liquid chromatography (FPLC). Pooled serum from control, TSC22D4, TBL1 and TBLR1 or 
TSC22D4, TBL1, TBLR1 shRNA adenovirus–injected C57BL/6J mice was applied to a Superose 6 
10/300 GL column 7 days after injection; (n=6). 
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Indeed, FPLC analysis revealed that the increased amounts of serum TGs detected 
upon TSC22D4 single, TBL1, TBLR1 double and TSC22D4, TBL1, TBLR1 triple 
deficiency were in all cases located in the VLDL fraction. All three groups had 
significantly higher VLDL TG peaks than control animals. The corresponding VLDL 
peaks (fraction 17) resulting from TSC22D4 single and TBL1 / TBLR1 double knock 
down were comparable, whilst triple knock down led to an even higher VLDL peak 
(Fig. 40 A). VLDL and HDL (fraction 33) cholesterol levels remained unaffected, as 
assessed by FPLC (Fig. 40 B). 
 
 
  
 
 
 
Fig. 41: Phenotypic analysis of TSC22D4, TBL1 and TBLR1 triple deficiency. Body weight (A), 
liver weight (B), fat weight (C), lean weight (D), blood glucose (E), liver cholesterol (F), serum 
NEFA (G), serum ketone bodies (H) and serum alanine transaminase (ALT) (I), in PBS, control 
TSC22D4, TBL1 and TBLR1 or TSC22D4, TBL1 and TBLR1 shRNA adenovirus–injected 
C57BL/6J mice 7 days after injection (means ± SEM, n ≥ 6). P < 0.05, * indicates significance. 
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Other metabolic parameters were generally not affected by any of the knock down 
conditions (Fig. 41 A-G). Only ketone body levels were, as expected (63), reduced in 
response to impeded beta oxidation in the absence of TBL1 and TBLR1 (Fig. 41 H).  
Serum alanine transaminase levels served as a marker for liver damage. No difference 
could be observed between PBS or virus treated animals (Fig. 41 I). 
 
5.3.9. Micro RNA mediated TSC22D4 knock down using adeno-
associated virus 
 
Adenoviral vectors are known to not only infect hepatocytes, but also other liver cells, 
including Kupffer macrophages. In order to analyze not only liver, but hepatocyte 
specific TSC22D4 knock down, an AAV-vector expressing a micro RNA (miRNA) 
against TSC22D4 was produced. The AAV serotype was designed to preferably infect 
hepatocytes and the miRNA was under the control of the hepatocyte-specific LP1 
promoter, which is not active in Kupffer or stellate cells (63). Transduction using 
AAV vectors leads to long-term knock down, since the virus does not provoke an 
immune reaction which would lead to its clearance, as is the case when using 
adenovirus (80). To investigate if obesity and insulin resistance influence the 
TSC22D4 deficient phenotype, C57BL/6J mice were put on either a high fat diet 
containing 60% energy from fat (HFD) or a low fat control diet (LFD) containing only 
10% energy from fat for 9 weeks.  
 
 
 
Fig. 42: Weight development of TSC22D4 deficient mice on a high fat diet. C57BL/6J mice 
injected with an adeno-associated virus (AAV) expressing either a control or a TSC22D4-specific 
micro RNA (miRNA). 3 weeks after injection, animals were either fed a high fat diet (HFD) containing 
60% energy from fat or a control low fat diet (LFD), containing 10% energy from fat (A). Fat mass of 
the mice was measured after 9 weeks of LFD or HFD feeding (B); (means ± SEM, n ≥ 4 ). P < 0.05, * 
indicates significance (TSC22D4 HFD vs. TSC22D4 LFD), # indicates significance (control HFD vs. 
control LFD). 
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5x 1011 infectious units of AAV were administered via the tail vein. Three weeks after 
infection, half the mice were put on the HFD and the other half were maintained on 
the LFD. As expected, over time the HFD fed mice put on significantly more weight 
than their LFD fed counterparts (Fig. 42 A). Their body fat content, as determined by 
Echo MRI, was also significantly higher after 9 weeks of diet (Fig. 42 B). No 
differences could be seen between control miRNA and TSC22D4-specific miRNA 
treated mice in regard to body composition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the sacrifice, knock down was assessed by quantitative PCR and Western blot 
analysis. A decrease in protein abundance was observed (Fig. 43 A) and mRNA levels 
were reduced by approximately 65 % (Fig. 43 B). During the experiment, blood had 
been taken from the tail vein every 2 - 3 weeks to investigate serum TG levels over 
Fig. 43: TSC22D4 knockdown using a miRNA expressing adeno-associated virus. 
Western blot analysis of liver extracts from mice injected with adeno-associated virus 
expressing a control or TSC22D4 specific miRNA using TSC22D4 and VCP specific 
antibodies 12 weeks after injection (A). Quantitative PCR analysis of TSC22D4 mRNA 
levels in livers of control or TSC22D4 miRNA-injected wild-type C57BL/6J mice (B). 
Serum triglyceride (TG) levels in the same mice 14 days after injection (C). Serum TG 
levels in the same mice 12 weeks after injection. Mice were fed either a diet containing 
10% energy from fat (LFD), or 60% energy from fat (HFD) for 9 weeks (D); means ± 
SEM, n ≥ 4). P < 0.05, * indicates significance. 
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time. Serum TGs were significantly elevated 2 weeks after infection with virus 
expressing the TSC22D4 specific-miRNA, copying the phenotype observed in the 
experiments using shRNA expressing adenovirus (Fig. 43 C). A decisive difference 
could however no longer be seen 12 weeks after transduction. At this time point, 
serum TG levels were slightly, albeit not significantly higher in the HFD fed TSC22D4 
deficient mice, whilst there was no difference at all between the LFD fed groups (Fig. 
43 D).  
 
In summary, these results confirm the involvement of TSC22D4 in the regulation of 
circulating serum TG levels, but point towards the presence of mechanisms capable 
of, at least in part, compensating for chronic TSC22D4 deficiency. Possibly other 
members of the TSC22 family are involved in these compensatory processes, as at 
least TSC22D1 can interact with TSC22D4. 
 
 
5.4 TSC22D4 over expression reduces circulating VLDL 
triglyceride levels in C57BL/6J mice 
 
 
Having seen that hepatic TSC22D4 deficiency leads to reduced liver TG levels, 
increased lipogenesis and elevated serum VLDL secretion, we sought to investigate 
the consequences of enforced TSC22D4 over expression. For this cause, an 
adenovirus encoding the TSC22D4 cDNA sequence in frame with the Flag peptide 
under the control of the constitutively active CMV promoter was cloned and 
produced. 
 
5.4.1. Hepatic TSC22D4 over expression in fasted and refed mice 
 
1x 109 infectious units of either TSC22D4 over expression virus, or an empty control 
virus incorporating the CMV promoter were administered to mice via tail vein 
injection. The mice were sacrificed 7 days after infection. To investigate the effects of 
starvation, the animals were fasted for 16 hours prior to the day of preparation. Half 
the mice were sacrificed in the fasted state, whilst the other half were refed for 6 
hours. 
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A significant increase in TSC22D4 expression was detected at the mRNA level by 
quantitative PCR analysis (Fig. 44 A). Approximately 40 times more TSC22D4 mRNA 
was present in mice treated with the over expression virus. Interestingly, less 
TSC22D4 expression was observed in the fed compared to the fasted state. This was 
true for mice treated with the control virus or the TSC22D4 over expressing virus, 
hinting towards up regulation of TSC22D4 upon fasting, a phenomenon that had 
previously not been seen. The recombinant TSC22D4 protein was visualized by 
Western blot using a Flag antibody. A strong signal, corresponding to the 
recombinant TSC22D4 protein could thereby be visualized (Fig. 44 B). 
 
5.4.1.1. Effects of TSC22D4 over expression on body composition 
 
TSC22D4 over expression induced no major changes concerning body or liver weight 
in the fasted or refed state (Fig. 45 A). A slight decrease was however measured in 
TSC22D4 over expressing animals in regard to fat weight (Fig. 45 B, C). Whilst no 
differences were detectable concerning fasting glucose levels, mice over expressing 
TSC22D4 had slightly but significantly elevated blood sugar content compared to fed 
empty virus treated mice (Fig. 45 D).  
 
Fig. 44:  Hepatic TSC22D4 over expression in fasted and refed mice. Quantitative PCR 
analysis of TSC22D4 mRNA levels in livers of control or TSC22D4 cDNA adenovirus-injected wild-
type C57BL/6J mice. Animals were fasted for 16 hours and refed for 6 hours (A). Western blot of 
liver extracts from representative fasted or refed control or Flag-TSC22D4 cDNA adenovirus–
injected C57BL/6J mice 7 days after injection using Flag and VCP antibodies (B); (means ± SEM, 
n > 4). P < 0.05, * indicates significance (control vs.TSC22D4), # indicates significance (fasted vs. 
refed). 
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5.4.1.2. Effects of TSC22D4 over expression on hepatic lipid metabolism 
 
As previously observed, liver TG stores were increased in fasted, as compared to refed 
mice. Upon TSC22D4 knock down, liver TG levels had been significantly reduced. In 
turn, over expression led to a slight increase in hepatic TG content, particularly in the 
fasted state (Fig. 46 A). Fasting liver cholesterol levels were also slightly elevated in 
the TSC22D4 group, there was however no difference in fed animals (Fig. 46 B). 
 
  
 
 
 
 
 
 
Fig. 45: Body composition of TSC22D4 over expressing mice. Fasting and refeeding body 
weight (A), liver weight (B), fat weight (C) and blood glucose levels (D) in control or Flag-TSC22D4 
cDNA adenovirus–injected C57BL/6J mice 7 days after injection; (means ± SEM, n≥4). P < 0.05, * 
indicates significance (control vs. TSC22D4). 
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Next, serum VLDL TG and HDL cholesterol levels were analyzed using FPLC. In 
knock down experiments, the major phenotype had been a marked elevation of 
circulating serum VLDL levels.  Indeed, hepatic TSC22D4 over expression induced 
the opposite effect. Whilst circulating HDL cholesterol was not affected (Fig. 47 A, B), 
VLDL TG levels were decreased by TSC22D4 over expression (Fig. 47 C, D). The 
effect was strongest in fasted mice, where hardly any VLDL peak was detectable. 
These data increase the evidence that TSC22D4 expression is integral in the 
regulation of VLDL metabolism. 
 
 
 
 
 
Fig. 46:  Hepatic triglycerides and cholesterol in TSC22D4 over expressing mice. Fasting and 
refeeding triglyceride (TG) (A) and cholesterol content (B) in livers of control or Flag-TSC22D4 
cDNA adenovirus–injected C57BL/6J mice 7 days after injection; (means ± SEM, n≥4). P < 0.05, * 
indicates significance. 
Fig. 47: Serum lipoprotein profiles of TSC22D4 over expressing mice. Lipoprotein-associated 
serum cholesterol levels as measured by fast protein liquid chromatography (FPLC) in 16 hour 
fasted (A) or 6 hour refed (B) mice injected with control or TSC22D4 over expression adenovirus. 
Lipoprotein-associated triglyceride levels in the same fasted (C) and refed (D) mice as above; 
(n≥3). 
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To investigate if the phenotype observed concerning hepatic and circulating VLDL TG 
levels was also reflected at the degree of lipogenic gene expression, mRNA levels of 
Acly, Acc1, Fasn, Scd1, Srebp1 and Lipin1 were assessed by quantitative real time 
PCR. No differences could be observed in fasted mice, probably as they are already in 
a state in which hepatic lipogenesis is generally repressed (Fig. 48 A). Lipogenesis 
was however significantly blunted upon TSC22D4 over expression in the fed state, 
indicating once more, that TSC22D4 is required for the proper induction of TG 
biosynthesis (Fig. 48 B). 
 
 
 
 
 
5.4.2. Fatty acid synthase is repressed by TSC22D4 
 
In order to demonstrate the involvement of TSC22D4 in the repression of lipogenesis 
in an in vitro setting, immortalized Hepa 1c1 mouse hepatoma cells were transfected 
with a vector encoding the fatty acid synthase (FasN) promoter in frame with the 
luciferase coding sequence. A second construct expressing either Flag peptide as a 
control, or Flag-TSC22D4 was co-transfected and a third vector encoding β-
galactosidase was used to normalize results. As was seen in in vivo experiments, 
TSC22D4 led to a dose dependent repression of FasN promoter activity (Fig. 49).  
In summary, these data support the hypothesis that TSC22D4 is directly involved in 
the regulation of lipogenic gene expression.  
 
Fig. 48: Lipogenesis is blunted in TSC22D4 over expressing mice. Quantitative PCR analysis of 
ATP citrate lyase (Acly), acetyl-coenzyme A carboxylase 1 (Acc1), fatty acid synthase (Fasn), 
stearoyl-CoA desaturase-1 (Scd1), sterol regulatory element-binding protein-1c (Srebp1) and Lipin1 
mRNA levels in  livers of 16 hour fasted (A) or 6 hour refed (B) control or TSC22D4 over expression  
adenovirus-injected wild-type C57BL/6J mice 7 days after injection; (means ± SEM, n > 4). P < 0.05, 
* indicates significance. Gene expression values are normalized to control 16 h fasted values. 
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5.4.3. Semi-endogenous co-immunoprecipitation 
 
Utilizing the presence of the Flag-tagged TSC22D4 protein in mice treated with the 
TSC22D4 over expression adenovirus, semi-endogenous co-immunoprecipitation 
studies were performed to verify the hepatic interaction with TBL1/TBLR1. For this 
purpose, we used anti-Flag agarose and 4 mg of hepatic protein lysate. Indeed, both 
TBL1 and TBLR1 co-precipitated with Flag-tagged TSC22D4 (Fig. 50), indicating that 
the observed interaction actually takes place in the liver and that TSC22D4, TBL1 and 
TBLR1, at least in part mutually contribute to the observed reduction in serum TG 
levels. As lipogenesis is controlled by all three of the proteins, it is likely that together 
they are involved in the repression of this process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 50: TBL1 and TBLR1 interact with TSC22D4 in the liver. C57BL/6J mice were 
infected with either Flag-TSC22D4 or empty control adenovirus. 7 days after injection 
Flag co-immunoprecipitation studies were performed with 4 mg of liver protein lysate. 
TBL1 (A) and TBLR1 (B) only co-precipitated in the presence of Flag-TSC22D4. 
Affinity purification was performed with an anti-Flag antibody. Bound proteins were 
resolved by SDS-Page and subsequently detected by Western blot. IN: input; EL: 
elution. 
 
Fig. 49: TSC22D4 represses fatty acid 
synthase promoter activity. Transient 
transfection assay of Hepa 1c1 hepatocytes 
cotransfected with a pGL2_FAS -150bp/-43bp 
FasN promoter construct and increasing 
amounts of TSC22D4 cDNA; (means ± SEM, n 
≥ 3). P < 0.05, * indicates significance. 
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5.4.4. Hepatic TSC22D4 restoration in obese mice 
 
Up until now, we had observed that TSC22D4 over expression leads to the opposite 
phenotype to TSC22D4 knock down and that mice fed a high fat diet express 
decreased amounts of TSC22D4 in the liver. The question therefore arose, whether 
restored TSC22D4 expression in livers of obese mice could counteract the associated 
pathological hypertriglyceridemia. To address this point, mice were fed either a 
control diet (LFD) containing 10% energy from fat or a high fat diet (HFD) containing 
60% energy from fat for 11 weeks. 10 days prior to sacrifice, 2x 109 infectious units of 
empty control or TSC22D4 over expression adenovirus were injected via the tail vein. 
The degree of obesity and any effects of TSC22D4 on body composition were assessed 
by weight and EchoMRi measurements. Mice fed the HFD were significantly heavier 
than LFD fed mice and also had more than double the amount of fat. No differences 
could however be seen between TSC22D4 over expressing and control mice 
concerning body composition (Fig. 51 A, B).  
 
 
 
 
 
Blood glucose levels were determined in fasted and fed mice. In the fasted state, no 
differences were measurable in lean mice. As expected, obese control mice had higher 
fasting blood glucose levels than LFD fed mice. Obese TSC22D4 over expressing 
animals, however, displayed fasting blood glucose levels comparable to those seen in 
lean individuals (Fig. 52 A). In the fed state, obese control mice again had higher 
blood glucose levels than lean animals. TSC22D4 over expression did not affect fed  
Fig. 51: Body weight and fat content of obese TSC22D4 over expressing mice. Body weight of 
control or Flag-TSC22D4 cDNA adenovirus–injected C57BL/6J mice 7 days after injection. Mice 
had previously been fed either a control low fat diet (LFD), or a high fat diet (HFD) for 12 weeks (A). 
Body fat content of the same mice as above (B); (means ± SEM, n=7). P < 0.05, * indicates 
significance (LFD vs. HFD). 
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blood glucose levels in obese mice, but did increase levels in lean mice, bringing them 
into the same range as seen in HFD fed animals, indicating that TSC22D4 over 
expression affects insulin signalling or glucose handling (Fig. 52 A). Mice were 
sacrificed in the random fed state. As expected, liver TG levels were elevated in HFD 
compared to LFD fed mice. In line with previous results, hepatic TG stores were 
larger in TSC22D4 over expressing mice when compared to their control counterparts 
(Fig. 53 A). The effect was strongest in lean mice, but a tendency was also visible in 
obese animals. Liver cholesterol levels were not affected by any of the observed 
conditions (Fig. 53 B). 
 
 
 
 
Fig. 52: Fasting and feeding blood glucose levels of obese TSC22D4 over expressing mice. 
Fasting (A) or feeding (B) blood glucose levels of control or Flag-TSC22D4 cDNA adenovirus–
injected C57BL/6J mice 7 days after injection. Mice had previously been fed either a control low fat 
diet (LFD), or a high fat diet (HFD) for 12 weeks; (means ± SEM, n=3). P < 0.05, * indicates 
significance (control vs. TSC22D4). # indicates significance (LFD vs. HFD). 
Fig. 53: Hepatic triglycerides and cholesterol in obese TSC22D4 over expressing mice. 
Hepatic triglyceride (TG) (A) and cholesterol (B) content of control or Flag-TSC22D4 cDNA 
adenovirus–injected C57BL/6J mice 7 days after injection. Mice had previously been fed either a 
control low fat diet (LFD), or a high fat diet (HFD) for 12 weeks; (means ± SEM, n=3). P < 0.05, * 
indicates significance (control vs. TSC22D4). 
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Serum cholesterol and TG content in the HFD fed mice were investigated after 
fractionation by FPLC. TSC22D4 over expression slightly blunted the HDL 
cholesterol peak, indicating that circulating lipoprotein metabolism was affected (Fig. 
54 A). The VLDL TG peak observed in mice treated with control virus was completely 
absent in TSC22D4 over expressing mice (Fig. 54 B). This result is in line with 
previous data and strengthens the hypothesis that TSC22D4 is involved in the 
suppression of VLDL release. 
 
 
 
Taking all the results obtained so far into account, one would expect that the 
observed decrease in circulating VLDL after TSC22D4 over expression results from 
defective VLDL secretion. To prove this is the case, a VLDL secretion assay was 
performed with HFD fed mice treated with control or TSC22D4 over expression 
adenovirus. In line with the previous observations, VLDL secretion was indeed 
reduced in these animals (Fig. 55). 
 
 
 
 
 
 
 
 
 
 
Fig. 54: Serum lipoprotein profiles of obese TSC22D4 over expressing mice. Lipoprotein-
associated serum cholesterol (A) and triglyceride (TG) (B) levels as measured by fast protein liquid 
chromatography (FPLC). Mice had previously been fed a high fat diet (HFD) for 12 weeks; (n=3). 
 
Fig. 55: TSC22D4 over 
expression leads to 
decreased VLDL secretion 
by the livers of obese mice. 
Hepatic very-low-density 
lipoprotein (VLDL) release in 
control or TSC22D4 over 
expression adenovirus-injected 
wild-type C57BL/6J mice. Time 
after tyloxapol injection 
indicated. Mice had previously 
been fed a high fat diet (HFD) 
for 12 weeks; (means ± SEM, n 
≥ 4). P < 0.05, * indicates 
significance. 
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5.5 TSC22D4 and cancer cachexia 
 
 
The phenotypes resulting from TSC22D4 knock down and over expression indicate 
that the gene is involved in the regulation of VLDL release by the liver. Judging from 
these data, one could speculate that TSC22D4 may play a role in the pathogenesis of 
tumour-associated cancer cachexia, a condition in which muscle and adipose tissue 
depots are depleted (81). One characteristic of the early stages of this disease is the 
development of hepatic steatosis in combination with low levels of circulating serum 
TGs (22). As this reflects the phenotype observed in mice over expressing TSC22D4, 
we analyzed mouse models associated with the development of cancer cachexia in 
regard to TSC22D4 expression. 
 
5.5.1. TSC22D4 is elevated in mouse models of wasting and cachexia 
 
5.5.1.1. TSC22D4 is induced by a methionine and choline deficient diet 
 
Mice fed a diet lacking methionine and choline (MCD), develop severe hepatic 
steatosis and have low serum TG levels. Choline is an important component required 
for the production of VLDL particles in the liver. Its absence results in defective 
VLDL assembly (82). Methionine deficiency, on the other hand, severely disrupts 
protein metabolism. As a consequence, mice lose large amounts of weight and fat 
content. Whilst this model does not directly reflect cancer cachexia, the conditions do 
have many similarities, concerning hepatic lipid metabolism and drastic weight loss.  
 
Mice were fed either a control diet or an MCD diet for 4 weeks. Indeed, the MCD-fed 
animals lost a significant amount of total body (Fig. 56 A) and fat weight (Fig. 56 B) 
during the course of the diet. As expected, serum TG levels were dramatically 
decreased (Fig. 56 C) and the livers accumulated large quantities of fat (Fig. 56 D). 
The expression of the lipogenic genes FasN and Srebp1 was blunted, as had been the 
case in TSC22D4 over expressing mice (Fig. 56 E). Importantly, TSC22D4 mRNA and 
protein were strongly up regulated in mice on the MCD diet, hinting towards an 
involvement in VLDL release under pathological conditions (Fig. 56 F, G). 
RESULTS 
 
62 
 
 
 
 
 
 
5.5.1.2. TSC22D4 levels correlate with weight loss in cachectic mice 
 
Based on the results obtained from the MCD fed animals, we investigated TSC22D4 
expression in cachectic Balb C mice. Ten animals were injected with 1.5 x 106 Colon 
26 (C26) murine adeno-carcinoma cells. Tumours started to visibly appear after 3-5 
days. The tumour implantation induced anorexia, weight loss and ultimately cachexia 
Fig. 56: TSC22D4 is induced by methionine and choline deficiency. Body weight (A) and fat 
content (B) of C57BL/6J mice fed a methionine and choline deficient diet (MCD) for 4 weeks. 
Serum (C) and liver (D) triglyceride (TG) levels of control or MCD fed mice after 4 weeks. 
Quantitative PCR analysis of fatty acid synthase (Fasn) and sterol regulatory element-binding 
protein-1c (Srebp1) expression in the same mice as above (E). Quantitative PCR analysis of 
TSC22D4 expression in the same mice as above (F). Western blot analysis of TSC22D4 
expression in a representative mouse from above (G); (means ± SEM, n = 6). P < 0.05, * indicates 
significance. 
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within a short time (data not shown). Mice were sacrificed three weeks after injection 
and the degree of cachexia was determined by calculating the amount of weight lost 
since tumour implantation. At the time of sacrifice, serum TG levels had significantly 
decreased in tumour bearing animals (Fig. 57 A). Interestingly hepatic TSC22D4 
expression was significantly increased in these cachectic mice (Fig. 57 B). More 
importantly, TSC22D4 expression levels correlated inversely with the degree of 
weight loss, indicating that TSC22D4 is induced during the onset of cancer cachexia 
(Fig. 57 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 57: TSC22D4 expression correlates with the degree of cachexia in mice. 
Male Balb C mice were injected with 1.5x 106 C26 mouse tumour cells. Serum 
triglyceride (TG) levels of control (PBS) or tumour-injected mice, 3 weeks after 
implantation (A). Quantitative PCR analysis of TSC22D4 expression in the same mice 
as above (B). Pearson’s correlation of log(2) of TSC22D4 expression and the per cent 
of initial weight at the time of sacrifice (C); (means ± SEM, n ≥ 6). P < 0.05, * indicates 
significance. 
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6. DISCUSSION 
 
The nuclear co-factors TBL1 and TBLR1 can associate with co-repressor complexes 
such as N-CoR/SMRT and Ctbp, leading to transcriptional repression of gene 
expression. Since both factors are also able to recruit co-activators and are required 
to switch on (de-repress) the expression of specific target genes, they are commonly 
referred to as nuclear co-repressor / co-activator exchange factors (59).  
 
In this study we identify transforming growth factor-beta 1 stimulated clone-22 D4 
(TSC22D4) as a novel TBL1 and TBLR1 interaction partner. TSC22D4 is located on 
human chromosome 5 and was first described due to its homology to the 
transforming growth factor-beta (TGFβ) responsive gene TSC22D1 (66,83,84). The 
two proteins are members of a family of four structurally related proteins (TSC22D1-
4) with a characteristic central interaction domain (TSC box), followed by a 
conserved leucine zipper structure. The N-terminal domains are less conserved, 
giving each member specific functions. TSC22D4 and TSC22D1 have been shown to 
homo- and heterodimerize via their leucine zippers and can both repress gene 
expression. The repressor activity is thereby probably localized in the N-terminus. 
TSC22D4 does not harbour a canonical DNA binding motif and may well be recruited 
to chromatin by interaction partners (66). Very little in vivo data is available 
concerning TSC22D4. The protein is induced during pituitary gland development and 
is involved in the differentiation of neuronal precursor cells. Indeed, TSC22D4 is 
expressed throughout the developing and adult brain (85,86). Furthermore, 
physiological stress conditions such as hyperosmotic stress in the kidney seem to 
favour TSC22D4 expression (84). The protein localizes in both the cytosol and the 
nucleus, whereby nuclear import seems dependent on external signals and is not 
mediated by a classical nuclear localization sequence (NLS) (87). In this regard, 
TSC22D4 is recruited to the nucleus of neuronal cells during the onset of apoptosis 
where it has been shown to interact with apoptosis inducing factor (AIF) (88,89). As 
its structural relative and interaction partner TSC22D1 is a known pro-apoptotic 
protein and tumour suppressor, one can speculate that TSC22D4 may also play a role 
in the regulation of cell survival and proliferation (90-93). There is currently little 
data available concerning mechanistic and tissue-specific functions of TSC22D4. This 
study provides first insights into the hepatic and physiological relevance of the gene 
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and identifies pathological conditions potentially linked to changes in TSC22D4 gene 
expression. 
 
We demonstrate that TSC22D4 knock down in the liver partially phenocopies hepatic 
TBL1/TBLR1 deficiency, as in both cases the expression of lipogenic genes is induced 
(63). We however also observe that TSC22D4 and TBL1/TBLR1 have divergent 
functions. Whilst TBL1 and TBLR1 are crucial in protecting the liver against steatosis, 
TSC22D4 reduces secretion of VLDL particles by the liver. In turn, this process 
increases hepatic TG stores. Consistently, TSC22D4 expression is reduced in mouse 
models of hypertriglyceridemia (pre-diabetes) and elevated in hypotriglyceridemia 
(cancer cachexia). In this discussion we will focus on the three aims of the study 
addressed on page 17. 
 
 
6.1 TSC22D4 interacts directly with TBL1/TBLR1  
 
 
We employed a cell-based, high throughput interaction screen to identify interaction 
partners of the transcriptional co-factors TBL1 and TBLR1. Both proteins have 
previously been shown to be components of large multi-protein complexes ranging 
up to 2 MDa in size (56,94). In the past, similar experiments not only identified the 
association of TBL1/TBLR1 with the N-CoR/SMRT and Ctbp co-repressor complexes, 
but also identified further dynamic complex components, such as the signalling 
molecule G protein pathway suppressor (GPS) 2 and nuclear receptors, including the 
master regulator of hepatic fatty acid oxidation PPARα (54,59,63,95). We chose to 
screen for novel TBL1/TBLR1 interaction partners using a LUMIER assay that was 
originally developed to analyze the TGFβ signalling pathway and has since been 
successfully modified and employed in several further studies (64,96,97). In our 
experiments, the bait consisted of a nuclear protein library. Although TBL1 and 
TBLR1 do have functional relevance in the cytosol and can interact with the mitotic 
spindle during cell division, transcriptional regulation in the nucleus seems to be 
their primary function (98). The screen was performed in HEK293T cells, as this cell 
line is easily transfected. Protein over expression is thereby a powerful tool when 
trying to identify transient interactions or the association of proteins with low 
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endogenous expression levels, as is the case for transcriptional co-factors. For both 
TBL1 and TBLR1, the strongest interaction signal resulted from co-transfection with 
the TSC22 family member TSC22D4. Currently there is only very little mechanistic 
and in vivo information available concerning this protein. It seems to have 
transcriptional repressor activity and to modulate cell proliferation and apoptosis 
(66,99). Due to the impressive strength of the interaction and the fact that the role of 
this gene is so far barely understood, we chose TSC22D4 as the target for further 
investigation.  
 
In follow-up experiments, we could show that the interaction between TBL1/TBLR1 
and TSC22D4 was of direct nature. Subsequently, we mapped the association to 
specific domains. TBL1 and TBLR1 possess three distinct protein motifs. The N-
terminal Lis1 homology (LisH) domain is required for the formation of TBL1/TBLR1 
homo- and heterodimers and also enables nuclear translocation of the co-repressors. 
By binding to histone H4 and N-CoR/SMRT, this domain is furthermore necessary 
for co-repressor complex assembly and activity (57,100). The LisH domain is 
followed by an F-Box region that recruits ubiquitin conjugating enzymes during de-
repression (58). Finally, the C-terminus of TBL1/TBLR1 consists of eight WD40 
repeats that form a β-transducin propeller structure. Each WD40 motif contains 
approximately 40 amino acids including a distinct tryptophan (W) / aspartic acid (D) 
dipeptide. β-transducin propellers act as platforms for the assembly of multi-protein 
complexes (57). Interestingly, TSC22D4 interacted with the TBL1/TBLR1 WD40 
domain. Whilst the first 105 TSC22D4 amino acids were not sufficient to mediate the 
interaction, the extended N-terminus ranging to amino acid 207 sufficed. The leucine 
zipper structure that mediates homo- and heterodimerization of TSC22 family 
members, as well as their association with other proteins did not seem necessary for 
protein-protein interaction (66). This was also the case for the characteristic TSC box 
which mediates the effects of TSC22 proteins in regard to cell proliferation and 
regulation of apoptosis (99,101). We were not successful in co-immonoprecipitating 
endogenous TBL1/TBLR1 and TSC22D4 in the liver, probably due to insufficient 
antibody quality and the generally low expression levels of co-factor proteins. Semi-
endogenous immunoprecipitation after transduction with an adenovirus over-
expressing Flag-TSC22D4 was however successful, demonstrating that the 
interaction is relevant in the mouse liver. In future it will be interesting to investigate 
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the influence of external signals and stimulants on complex formation in either an in 
vivo or cell-autonomous ex-vivo setting. 
 
During the LUMIER screens we also observed that TBL1 and TBLR1 interact with 
another TSC22 family member, namely TSC22D1. Members of our laboratory have in 
the mean time recapitulated this interaction by co-immunoprecipitation 
(unpublished data). It will be interesting to perform GST pull-down assays and see if 
the association with TSC22D1 is also of direct nature, or if heterodimerization with 
TSC22D4 is required to link both proteins to the co-repressors. Previous work on the 
common Drosophila melanogaster TSC22 precursor bunched suggests that TSC22D4 
and TSC22D1 may at least in part have antagonizing effects in regard to cell 
proliferation (102,103). Indeed, understanding the interplay between TBL1/TBLR1 
and TSC22 family members could in the future uncover complex regulatory networks.  
 
 
6.2 TSC22D4 represses VLDL secretion 
 
 
TSC22D4 loss and gain of function studies were performed in the livers of adult mice. 
Transient manipulation of gene expression using adenovirus was the method of 
choice, as genetic TSC22D4 knock-out or over expression mouse models are currently 
not available. It is furthermore unknown whether such animals would be viable, or if 
their development would be hindered by the prenatal deregulation of TSC22D4. 
Furthermore, genetic mouse models occasionally have no phenotype, as the effects 
are compensated by other genes during development (65,104). This is less likely in 
transient studies, as the adult body only has little time to adapt to changes in gene 
expression. Furthermore, particular genes might exert specific functions during 
development which differ from those in the adult organism. Consequences of these 
effects are avoided in conditional genetic models or by using viral systems. TSC22D4 
has been suggested to work as a transcriptional co-factor (66). Although evidence for 
its role as a co-repressor is limited, the interaction with nuclear co-repressor / co-
activator exchange factors TBL1 and TBLR1 supports the hypothesis. As the 
TBL1/TBLR1 co-factors govern important metabolic checkpoints, we chose to 
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investigate the liver-specific functions of TSC22D4, especially in regard to previous 
data published by Kulozik et al. in 2011. 
 
In the absence of hepatic TSC22D4, lipogenic gene expression was enhanced. VLDL 
secretion was markedly increased whilst hepatic TG stores were reduced, indicating 
that excess TGs resulting from de novo lipogenesis were immediately shuttled out of 
the liver. In proof of this principle, TSC22D4 over expression had opposing effects, 
namely reduced lipogenic gene expression and lower VLDL secretion while TGs 
accumulated in the liver. It is known that upon stimulation of lipogenesis, newly 
synthesized lipids can be directly incorporated into VLDL and that lipogenesis per se 
enhances VLDL secretion in humans (105,106). It has also previously been shown 
that silencing of certain lipogenic genes induces a phenotype resembling that 
resulting from TSC22D4 over expression, a setting in which we observed that these 
lipogenic genes were down regulated. Indeed, knock down of ATP-citrate lyase (Acly), 
a key lipogenic enzyme required to convert citrate to acetyl-CoA, results in reduced 
lipogenesis and VLDL secretion, whilst hepatic TG stores are increased (107). Whole 
body Acly inhibition thereby favours hypolipidemia and prevents weight gain when 
mice are fed a high fat diet (108-110). Similar results were observed when Stearoyl-
CoA desaturase (Scd1) was inactivated, again cumulating in reduced lipogenesis and 
VLDL secretion (111,112). TBL1/TBLR1 double knock down had the same 
consequences as TSC22D4 deficiency in regard to lipogenic gene expression. As this 
process is both directly and indirectly regulated by the nuclear receptor Liver X 
receptor (LXR), it is tempting to speculate that TSC22D4, TBL1 and TBLR1 mutually 
repress LXR activity and, in turn, inhibit lipogenesis. Future experiments focusing on 
LXR target gene promoter activity may shed more light on the molecular mechanisms 
underlying these particular transcriptional control events. 
 
Unlike TBL1/TBLR1 ablation, TSC22D4 deficiency did not reduce β-oxidation or 
inhibit VLDL uptake by the liver (63). This points towards independent roles for each 
co-factor and indicates that whilst TSC22D4 may well be incorporated into 
TBL1/TBLR1 co-repressor complexes governing lipogenesis, it does not seem to be 
involved in PPARα associated TBL1/TBLR1 co-activator structures. This is in line 
with previous reports stating that TSC22D4 had repressive, but not activating 
capacity (66). Unlike TBL1/TBLR1, TSC22D4 seems to regulate hepatic VLDL 
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secretion. Healthy wild type mice secrete up to 50 mg of TG per day, implying that 
chronically elevated VLDL secretion will over time greatly increase serum TG load, 
but at the same time may act as an effective mechanism in protecting against hepatic 
steatosis (113). So far, only few genes are known that significantly regulate VLDL 
secretion. Microsomal triglyceride transfer protein (MTP) 1 facilitates apoB and 
subsequently VLDL maturation. MTP1 mutations are associated with 
hypoapolipoproteinemia and accompanied by reduced VLDL secretion (114). MTP1 
expression was however not affected by TSC22D4 manipulation. The expression of 
Lipin1, another gene linked to VLDL secretion, was significantly up regulated upon 
TSC22D4 knock down and down regulated upon TSC22D4 over expression. No 
significant changes in Lipin1 expression were observed in TBL1/TBLR1 experiments. 
Lipin1 is a phosphatidate phosphatase that associates with microsomal membranes in 
the ER and catalyses the penultimate step in glycerolipid biosynthesis, namely the 
conversion of phosphatic acid to diacylglycerol (115). Previous studies have 
demonstrated that Lipin1 actively enhances VLDL secretion by hepatocytes and also 
increases intracellular apoB stability. Conversely, the same studies demonstrated that 
Lipin1 depletion decreases VLDL release by the liver (116). Interestingly, 
glucocorticoid treatment seems to induce Lipin1 expression, which may explain the 
increase in VLDL secretion often occurring as a side effect during glucocorticoid 
treatment (117). As we have shown that TSC22D4 expression is reduced in mice 
chronically injected with dexamethasone, it is plausible that TSC22D4 may partake in 
the inhibition of Lipin1 activation in untreated mice. Whilst these data open 
interesting hypotheses and link TSC22D4 to Lipin1, it must be noted that another 
study using fatty liver dystrophy (fld) mice, a genetic mouse model characterized by a 
Lipin1 null mutation, has delivered conflicting results. Whilst the mice did display 
hepatic steatosis, in this setting Lipin1 deficiency had the exact opposite effect 
regarding serum TG levels. The mice displayed serum hypertriglyceridemia due to 
enhanced VLDL secretion (118). The reasons underlying the observed discrepancies 
are so far not understood. Chronic, systemic Lipin1 deficiency is perhaps 
compensated by the other members of the lipin family, namely the phosphatidate 
phosphatases lipin 2 and lipin 3 (115).    
 
It is known that in the long run, increased hepatic lipogenesis leads to dyslipidemia 
and insulin resistance (119). Glucose and insulin tolerance were not affected in 
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transient TSC22D4 knock down experiments. The insulin signalling cascade was 
however blunted, indicating primary defects in glucose metabolism. It is plausible 
that hepatic TSC22D4 deficiency alone is not sufficient to induce full-blown insulin 
resistance and glucose intolerance. Interestingly, unpublished data obtained in our 
laboratory indicate that TSC22D4 deficiency in adipose tissue leads to reduced 
lipogenesis accompanied by increased lipolysis. Indeed, in these studies the same 
lipogenic genes, including Acly and Scd1 were deregulated, albeit in the opposing 
direction. As these effects also favour the development of type 2 diabetes (15) it would 
be of great interest to study full body TSC22D4 knock-out animals in regard to 
systemic insulin sensitivity. In this respect, it is however important to keep in mind 
that the effects on lipid metabolism were compensated in long-term hepatic 
TSC22D4 deficiency, perhaps by related proteins. As all TSC22 family members can 
potentially homo- and heterodimerize and have a common precursor in Drosophila 
melanogaster (66), it is possible that knock down of more than one family member is 
required to observe long-term metabolic consequences. As mentioned above, the 
interplay between different TSC22 family members and transcriptional regulation is 
of great interest.  
 
 
6.3 TSC22D4 in health and disease 
 
 
6.3.1. TSC22D4 and obesity 
 
Hepatic TSC22D4 expression is reduced in obese and pre-diabetic mice whilst serum 
TG levels are elevated upon hepatic TSC22D4 knock down. It is therefore plausible 
that the regulation of this gene may have implications for the pathogenesis of obesity-
related hypertriglyceridemia. The reduction in hepatic TSC22D4 expression under 
obese conditions may however also serve to protect already steatotic livers against 
further TG accumulation. TSC22D4 expression is also reduced in 
hyperglucocorticoidemia, a condition characterized by increased de novo lipogenesis 
(71). This, in turn, indicates that TSC22D4 may play a role in the occurrence of 
hypertriglyceridemia as a side-effect of chronic glucocorticoid (e.g. dexamethasone) 
treatment, a process that is also governed by changes in Lipin1 expression (117).  
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6.3.2. TSC22D4 and carcinogenesis 
 
In recent years, the connections between metabolic disorders and tumour 
development have become increasingly evident (120). Malignant cells display 
characteristic changes in metabolic regulation to favour cell proliferation. In a 
process known as the Warburg effect, for example, cells shift their energy-producing 
capacity from oxidative phosphorylation towards less efficient aerobic glycolysis. This 
shift increases the immediate uptake and incorporation of nutrients into the biomass 
and induces rapid cell proliferation (20,121). Several genes which were previously 
considered to be classical regulators of lipid metabolism have recently been shown to 
play a role in the regulation of cell proliferation. Acly is, for example, up regulated in 
lung adenocarcinoma cells. Consistently, Acly knock down not only reduces de novo 
lipogenesis, but also induces growth arrest and protects against proliferation (122). 
Another study demonstrated that inhibition of the lipogenic gene FasN impairs 
cellular proliferation and actively induces apoptosis (123). As TSC22D4 has been 
suggested to function as a tumour suppressor, its negative regulation of potentially 
tumourigenic, lipogenic gene expression may present a new node linking metabolic 
control with carcinogenesis. Indeed, Acly and FasN were both amongst the genes 
most prominently affected by changes in TSC22D4 expression and were both strongly 
up regulated in the absence of TSC22D4. At this point it is important to add that in 
another study we have observed significantly elevated levels of TSC22D4 expression 
in pancreatic tumour samples when compared to healthy control tissue (unpublished 
observation). These data indicate that, at least in the pancreas, TSC22D4 may also act 
as an oncogene. In this regard, whilst most publications imply that the TSC22 gene 
family has anti-proliferative, tumour suppressive capacity there has also been some 
evidence that the Drosophila melanogaster TSC22D4 homolog bunched promotes 
cellular proliferation (102,103). In future it will be interesting to address the links 
between TSC22D4 and cancer in more detail. Understanding potential pro- or anti-
tumourigenic activity is important when considering TSC22D4 as a potential drug 
target. Analysis of human liver cancer samples in regard to expression of TSC22 
family members will help when investigating these processes. Subsequently, as 
TSC22 proteins are implicated with the regulation of cell death, apoptosis assays and 
cell-survival studies may give new functional insights into the relevance of TSC22D4.  
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6.3.3. TSC22D4 and cancer cachexia 
 
Whilst hepatic TSC22D4 expression was down regulated in obesity, expression was 
markedly increased in cancer cachexia, a catabolic condition in which peripheral TG 
levels are decreased but hepatic TG stores are elevated (22). There was a clear 
negative correlation between TSC22D4 mRNA levels and the degree of wasting, 
indicating a role for TSC22D4 in the control of liver catabolism. In patients, survival 
prognosis worsens with increased loss of muscle and adipose tissue (21), suggesting 
that TSC22D4 may act as a hepatic marker for cancer progression and outcome. The 
reduction of VLDL release from cachectic livers may thereby be controlled by 
TSC22D4. In future, it will be important to understand whether changes in hepatic 
TSC22D4 expression are causal in cachexia progression. It this regard, TSC22D4 may 
inhibit the distribution of TGs throughout the wasting body. Alternatively, TSC22D4 
may coordinate protective mechanisms by which hepatic TG stores are protected for 
the final stages of wasting in which no peripheral energy sources are available. In 
either case, TSC22D4 is a potentially attractive drug target in the search for anti-
cachexia treatment strategies, of which currently only few exist (21). Understanding 
the signals required to modulate TSC22D4 expression in the different disease 
condition will be of utmost importance when trying to find compounds that influence 
TSC22D4 activity. 
 
 
6.4 Summary and outlook 
 
 
In summary, we have identified a novel physical interaction between TBL1/TBLR1 
and TSC22D4. Whilst all three genes are involved in the suppression of hepatic 
lipogenesis, they also have distinct roles in the liver. TSC22D4 thereby inhibits VLDL 
release and consequently regulates both hepatic and serum lipid metabolism (Fig. 
58). Down regulation of TSC22D4 was seen in mouse models of pre-diabetes 
(hypertriglyceridemia) whilst expression levels were elevated in cachectic mice 
(hypotriglyceridemia). The implications associated with these changes in gene 
expression remain to be characterized, as do the precise molecular mechanisms by 
which TSC22D4 regulates lipogenic gene expression. In vitro promoter activity 
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assays and chromatin immunoprecipitation studies will be required to shed light on 
these issues. We have furthermore presented preliminary data indicating that 
TSC22D4 is involved in tumour development. Further experiments in this direction, 
including cell proliferation assays, are of great interest and may produce another 
potent link between molecular transcriptional control and tumour development. In 
the light of these first in vivo data, the generation of inducible tissue-specific or full 
body TSC22D4 knock-out and over expression mice is worth considering. 
  
Fig. 58: Effects of TSC22D4 manipulation on hepatic lipid metabolism. In the absence of 
TSC22D4, apolipoprotein (Apo) B stability is increased and lipogenic gene expression is induced. 
Lipids are subsequently packaged into very low density lipoprotein (VLDL) particles and shuttled 
from the liver. In contrast, TSC22D4 over expression leads to reduced lipogenesis and lower VLDL 
secretion, whilst triglycerides accumulate in the liver (orange colour). A similar phenotype can be 
seen in cancer cachexia, a condition in which hepatic TSC22D4 expression is elevated.  
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7. MATERIAL 
 
7.1 Instruments 
       
   
Instrument      Distributor   
Analytical scales      Satorius, Göttingen 
Bacterial shaker      Infors AG, Böttmingen, CH 
Blotting chamber      Bio-Rad, Munich 
Camera (Power Shot G6)     Canon, Krefeld  
Cell counter       Neolab, Heidelberg 
Centrifuge (2K15)      Sigma, Munich 
Centrifuge (Biofuge fresco)    Heraeus, Hanau   
Centrifuge (Biofuge pico)     Heraeus, Hanau 
Centrifuge (Function Line)    Heraeus, Hanau 
Centrifuge (Micro 22R)     Hettich GmbH & Co, Tuttlingen 
Centrifuge (Super T21)      Heraeus Sorvall, Langenselbold 
Centrifuge (XL 70 Ultracentrifuge)   Beckmann, Munich   
CO2-incubator      Sanyo, Munich 
CO2-incubator (Forma Scientific)   Labotect, Göttingen 
Electrophoresis chamber      Steinbrenner, Wiesenbach 
Electrophoresis power supply (Power Pack Basic) Bio-Rad, Munich 
Electrophoresis power supply (Power Pack HC) Bio-Rad, Munich 
Electroporator (Gene PulserII)    Bio-Rad, Munich 
Film cassette       Amersham, Freiburg 
Film developer      Amersham, Freiburg 
FPLC-Äkta GE Healthcare, Salt Lake City, 
USA 
Fridge, 4°C       Liebherr, Biberach 
Gas stove (GASI)      Schütt, Göttingen 
Gel documentation station    Bio-Rad, Munich 
Heat block       VWR, Darmstadt 
Heat block (Thermostat Plus)     Eppendorf, Hamburg 
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Horizontal shaker (Duomax 1030)   Heidolph, Kehlheim 
Hotplate / stirrer      VWR, Darmstadt 
Incubator (Function Line)     Heraeus, Hanau 
Luminometer microplate LB 940   Berthold Tech., Bad Wildbad 
Microscope (Axiovert 40 CFL)    Carl Zeiss, Jena 
Microwave       Bosch, Stuttgart 
Multistep-pipette      Eppendorf, Hamburg 
Neubauer counting chamber    Carl Roth GmbH, Karlsruhe 
Nitrogen tank Thermo Electron coorp., 
Erlangen 
One Touch Glucose monitor    Lifescan, Neckargemünd 
pH-meter       VWR, Darmstadt 
Photometer (Nano Drop-1,000)    Peqlab Biotechnology, 
Erlangen  
Photometer        Amersham, Freiburg 
Pipette controller      Brand, Wertheim 
Pipettes       Gilson, Middleton, USA 
Rotating wheel      Neolab, Heidelberg 
Scales (BL 1500 S)      Satorius, Göttingen 
Scanner       Epson, Meerbusch 
SDS-electrophoresis chamber    Bio-Rad, Munich 
Sonifier 250       Branson, Danburry, Co., USA 
Sterile bench (Class II Type A/B3)   Sterilgard, Sanford, USA 
Stand        Carl Roth GmbH, Karlsruhe 
Tabletop centrifuge (Mini Spin Plus)   Eppendorf, Hamburg 
Tabletop scales Kern und Sohn GmbH, 
Bahlingen 
Thermocycler (PTC-200)     Biozym, Oldendorf 
Thermostatic water bath (WBS)    Fried Electric, Haifa, IL 
Tissue lyzer       Qiagen, Hilden 
Upright freezer, -20°C (Comfort)    Liebherr, Biberach 
Upright freezer, -80°C (Hera Freeze)   Heraeus, Heilbronn 
Vortex mixer (REAX 2,000)    Heidolph, Kehlheim 
Water bath       Neolab, Heidelberg 
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Water vacuum pump     Neolab, Heidelberg 
 
 
7.2 Consumables 
 
 
Product       Distributor 
Cell scrapers (Costar®)     Corning Inc., NY, USA 
Centrifuge tubes (35 ml)     Beckmann, Munich 
Polyallomer tubes (25mm x 89 mm)   Beckmann, Munich 
Polyallomer tubes (25mm x 89 mm)   Beckmann, Munich 
Protein columns (800 µl) (Mobicol)   MoBiTec, Göttingen 
Protein columns (2.5 ml)     MoBiTec, Göttingen 
Cover slips       Carl Roth GmbH, Karlsruhe 
Cryo tubes (2 ml)      Symport, Beloeil, CA 
Cuvettes       Greiner, Frickenhausen 
Dialysis tubing (MWCO 15.000; 10 mm diameter) Carl Roth GmbH, Karlsruhe 
Disposable scalpels      Feather, Cuome, JP 
DNase / RNase free water     Invitrogen, Karlsruhe 
Electroporation cuvettes     Steinbrenner, Wiesenbach 
Filters for Mobicol columns (35 µm)   MoBiTec, Göttingen 
Filters (0.45 µm)      Millipore, Eschborn 
Flag-agarose       Sigma, Munich 
Gel staining boxes (Mini)     Carl Roth GmbH, Karlsruhe 
Gloves (Safe Skin Purple Nitrile)    Kimberly Clark, BE 
Gloves (Proline Vinyl)     Asid Bonz GmbH, Herrenberg 
Gradient gels 4-12% (NuPage)    Invitrogen, Karlsruhe 
HyperfilmTM ECL      Amersham, Freiburg 
Micro test tubes (1.5 ml, 2 ml)     Steinbrenner, Wiesenbach 
Mouth protection      Meditrade, Kiefersfelden 
Nitrocellulose membrane     Schleicher and Schüll, Dassel 
Parafilm       Pechinery Inc., Wisconsin, USA 
Pasteur pipettes       Brand, Wertheim 
PCR tubes (200 µl)      Eppendorf, Hamburg 
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Petri dishes       Greiner, Kremsmünster, AU 
Pipette tips (0.1 – 1,000 µl)    Starlab, Helsinki, FI 
Pipette tips (0.1 – 1,000 µl) (Tip One® Filter Tips) Starlab, Helsinki, FI 
Pipette tips (Electrophoreses / Protein)   Bio-Rad, Munich 
Rabbit IgG-agarose      Sigma, Munich 
Safelock micro test tubes (1.5 ml and 2 ml)  Eppendorf, Hamburg 
Saran cling film Dow Chem. Co., Schwalbenbach 
Serotological pipettes (5 ml, 10 ml, 25 ml, 50 ml) BD Biosciences, San Jose, USA 
Syringes (10 ml Luer Lock)    Terumo, Leuven, BE 
Syringes (50 ml)      Terumo, Leuven, BE 
Test tubes (15 ml and 50 ml)    Falcon, Gräfeling-Lochham 
Tissue culture dishes (10 cm and 15 cm)   Falcon, Gräfeling-Lochham  
Vivaspin Concentrator     Vivascience, Hannover 
Whatman paper      Whatman Int., Ltd., UK 
1-stack cell culture dishes     Sigma, Munich 
10-stack cell culture dishes    Sigma, Munich 
6-well tissue culture dishes    Falcon, Gräfeling-Lochham 
12-well tissue culture dishes    Corning Inc., NY, USA 
96-well MicroAmp™ plates    Applied Biosystems, Darmstadt 
96-well Microtiter® luminescense plates  Nunc, Wiesbaden 
 
 
7.3 Chemicals and reagents 
 
 
Chemical       Distributor 
Acetic acid (99%)      Sigma, Munich 
Acrylamide-bisacrylamide Solution (37.5 : 1)   Carl Roth GmbH, Karlsruhe 
Adenosine triphosphate (ATP)    Sigma, Munich 
Agarose        Sigma, Munich 
Ammonium persulfate (APS)     Carl Roth GmbH, Karlsruhe 
Ampicillin        Sigma, Munich 
Aprotinin       Sigma, Munich 
Benzonase       Novagen, Darmstadt 
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Bis-Tris       Sigma, Munich 
Boric acid        Sigma, Munich 
Bovine serum albumin (BSA)     Sigma, Munich 
Bromophenol blue       Sigma, Munich 
Calcium chloride      Sigma, Munich 
Chloramphenicol      AppliChem, Darmstadt 
Colloidal coomassie Brilliant Blue G   Sigma, Munich 
Desoxynucleotides (dATP, dCTP, dGTP, dTTP)  Roche, Mannheim 
Dipotassium phosphate      Applichem, Darmstadt 
Disodium hydrogen phosphate    Sigma, Munich 
DMSO (Dimethyl sulfoxide)     Sigma, Munich 
DTT (Dithiothreitol)      Sigma, Munich 
Dulbecco’s modified Eagle’s medium (DMEM)  Invitrogen, Karlsruhe 
EDTA (Ethylenediaminetetraacetic acid)   Sigma, Munich 
EGTA (Ethylenglycoltetraacetic acid)    Sigma, Munich 
Ethanol (99%)      DKFZ 
Ethidium bromide       Carl Roth GmbH, Karlsruhe 
Fetal calf serum (FCS)     Invitrogen, Karsruhe 
Glucose       Sigma, Munich 
Glutathione sepharose     Amersham, Darmstadt 
Glycerol        Baker, Deventer, NL 
Gly-Gly       Sigma-Aldrich, Munich 
Hepes        Roth, Karlsruhe 
Huminsulin Normal 40 Lilly, Bad Homburg 
Hydrochloric acid (HCl) 37%  Acros Organics, New Jersey, 
USA 
Igepal (Nonidet NP40)     Sigma, Munich 
Imidazole       Merck, Darmstadt 
Isopropanol        Sigma, Munich 
Isopropyl-β-D-thio-galactopyranoside (IPTG)  Sigma-Aldrich, Munich 
LB-Agar       Carl Roth GmbH, Karlsruhe 
LB-Medium        Carl Roth GmbH, Karlsruhe 
Lipofectamine      Invitrogen, Karlsruhe 
Leupeptin       Sigma, Munich 
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Loading dye solution (6x)     Fermentas, St. Leon Rot 
Luciferin        Sigma, Munich 
Magnesium chloride (MgCl2)    Merck, Darmstadt 
Magnesium sulfate (MgSO4)    Sigma, Munich 
β-Mercaptoethanol  (98%)    Sigma, Munich 
Methanol (100%)      Merck, Darmstadt 
Methionine (35S radiolabelled)    Perkin Elmer, Rodgau 
Milk powder Rapilait     Migros, Lörrach, CH 
Minimal Essential Medium (MEM)   Invitrogen, Karlsruhe 
Monosodium phosphate (NaH2PO4)    Applichem, Darmstadt 
Non essential amino acids     Invitrogen, Karlsruhe 
3-(N-morpholino)propanesulfonic acid (MOPS) Carl Roth GmbH, Karlsruhe 
o-Nitrophenyl-β-D-galactopyranosid (ONPG)  Sigma, Munich 
Oil red O       Sigma, Munich 
Orange G       Sigma, Munich 
PageBlueTM protein staining solution   Fermentas, St. Leon-Rot 
Penicillin / Streptomycin (P/S)    Invitrogen, Karlsruhe 
Pepstatin       Sigma, Munich 
Ponceau-S Solution      Sigma, Munich 
Potassium chloride (KCl)      Sigma, Munich 
Proteinase inhibitor cocktail    Roche, Penzberg 
Phosphatase inhibitor cocktail    Roche, Penzberg 
Qiazol        Qiagen, Hilden 
Tripotassium phosphate (K3PO4)    Merck, Darmstadt 
Trypsin-EDTA       Invitrogen, Karlsruhe 
Sheep-anti-rabbit IgG magnetic beads   Invitrogen, Karlsruhe 
Sodium acetic acid (NaCH3COOH)   Sigma, Munich 
Sodium chloride (NaCl)      Fluka, Munich 
Sodium dodecyl sulfate (SDS)  Gerbu, Biotechnik GmbH, 
Gaiberg 
Sodium fluoride (NaF)     Sigma, Munich 
Sodium hydroxide (NaOH)    Sigma, Munich 
Sodium orthovandate     Sigma, Munich  
Spectinomycin      Sigma, Munich 
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N,N,N’,N’-Tetramethylenediamine (TEMED)   Carl Roth GmbH, Karlsruhe 
Triton X-100       Sigma, Munich 
Tris base        Sigma, Munich 
Trypsin-EDTA solution     Invitrogen, Karlsruhe 
Tween-20       Sigma, Munich 
Urea         Sigma, Munich 
Williams Medium E     Sigma, Munich 
 
 
7.4 Commercial kits 
 
 
Kit        Distributor 
BLOCK-iTTM U6 RNAi Entry Vector Kit    Invitrogen, Karlsruhe 
BLOCK-iTTM Adenoviral RNAi Expression System Invitrogen, Karlsruhe 
Cholesterol determination Kit    Randox, Crumlin, UK 
Enhanced Chemiluminescence (ECL) Kit  Amersham Biosciences, 
Freiburg 
First Strand cDNA Synthesis Kit Fermentas, St. Leon-Rot,  
Insulin ELISA Kit      Mercodia, Uppsala, S 
Invitrogen Pure-Link™ High Pure Plasmid   Invitrogen, Karlsruhe  
Ketone bodies Determination Kit    Wako, Neuss 
NEFA – C Determination Kit     Wako, Neuss 
Platinum® Quantitative PCR Supermix   Invitrogen, Karlsruhe 
QiaPrep Plasmid Miniprep Kit     Qiagen, Hilden 
QiaQuick Gel Extraction Kit     Qiagen, Hilden 
RNeasy RNA Extraction Kit Qiagen, Hilden 
TN T T7/T3 Coupled Reticulocyte Lysate System Promega, Mannheim 
Triglycerides Determination Kit  Sigma-Aldich Chemicals 
GmbH, Steinheim 
Triglycerides Liquicolour      Human GmbH Wiesbaden 
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7.5 Research diets 
 
 
High fat diet (60% energy from fat)   New Brunswick, USA 
Low fat diet (10% energy from fat)   New Brunswick, USA 
Methionine, choline deficient diet   New Brunswick, USA 
 
 
7.6 Solutions and buffers 
 
 
BBS (2x) 
Components: 50 mM   BES 
   280 mM   NaCl 
   1.5 mM   Na2HPO4 
   pH 6.95 
 
Blocking buffer (for Western blotting) 
Components: 1x    PBS 
   0.1%    Tween 20 
   5%    Milk powder 
 
Co-immunoprecipitation buffer 
Components: 20 mM    HEPES/KOH  
125 mM    NaCl 
0.5 mM    EDTA  
0.1%     Igepal  
10%     Glycerol 
1x     Protease inhibitor 
pH 7.4 
 
Gly-Gly working solution (WS) 
Components: 25 mM    Gly-Gly  
15 mM    MgSO4  
4 mM     EGTA 
   pH 7.8 
 
HANKS I buffer 
Components: 8 g     NaCl  
   0.4 g     KCl 
   3.57 g    Hepes 
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   0.06 g    KH2PO4 
   0.06 g    Na2HPO4 x 2 H2O 
   add 1L    Distilled H2O 
2.5 mM    EGTA 
   0.1%     Glucose 
pH 7.4 
 
HANKS II buffer 
Components: 8 g     NaCl  
   0.4 g     KCl 
   3.57 g    Hepes 
   0.06 g    KH2PO4 
   0.06 g    Na2HPO4 x 2 H2O 
   add 1L    Distilled H2O 
3 mg/ml    Collagenase CLSII   
 5 mM     CaCl2 
0.1%     Glucose 
pH 7.4 
 
Harvest buffer (for luciferase assays) 
Components: 100%     Gly-Gly WS  
1%     Triton X-100 
1 mM     DTT 
 
Luciferase assay buffer  
Components: 20 mM    K3PO4 
80%     Gly-Gly WS 
1.6 mM    DTT  
2 mM     ATP 
pH 7.8 
 
Luciferin solution  
Components: 1 mM     Luciferin  
10 mM    DTT   
Dissolved in Gly-Gly WS 
 
ONPG buffer 
Components:  0.1 M     NaPi 
1 mM     MgCl2  
10 mM    KCl  
1 mg/ml    ONPG  
100 mM    ß-Mercaptoethanol 
pH 7.5 
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Orange G sample buffer (6x) 
Components:  10 mM    EDTA 
70%     Glycerol 
   1 spatula tip   Orange G 
 
PBS (10x) 
Components:  1.4 M     NaCl 
27 mM    KCl 
100 mM    Na2HPO4 
8 mM    KH2PO4  
pH 6.8 
 
PBS-T 
Components: 1x     PBS  
0.1%     Tween-20  
 
Protease-inhibitor mix (50x)  
Components: 50 mM    PMSF  
50 mM    NaF  
0.5 mg/ml    Leupeptin  
0.5 mg/ml    Aprotinin  
0.5 mg/ml    Pepstatin A 
   Dissolved in ethanol 
 
Protein lysis buffer 
Components: 50 mM    Tris  
1 mM     EDTA  
10 mM   NaF  
2 mM    Na3VO4  
1 mM    DTT 
1x    Protease-inhibitor mix 
pH 7.2 
 
Supplement:  1.5 M     NaCl 
   1%    NP-40 
   
SDS running buffer (10x) 
Components:  0.25 M    Tris-base 
1.92 M   Glycine 
1%     SDS 
 
 
 
 
MATERIAL 
 
84 
 
TBE buffer (10x) 
Components:  45 mM    Tris Base 
10 mM    EDTA 
45 mM   Boric acid 
 
TE buffer (10x) 
Components:  1 mM     EDTA 
10 mM    Tris-HCl  
pH 8 
 
Transfer buffer SDS-PAGE 
Components:  25 mM    Tris-base 
192 mM    Glycine 
20%    Methanol 
0.01%    SDS 
 
All buffers were diluted in H20, unless stated otherwise. 
 
 
7.7 Molecular components 
 
 
Antibodies 
Antibodies were diluted in blocking buffer prior to use. The dilution factor of primary 
antibodies ranged from 1:100 to 1:5,000 depending on the specifications given by the 
distributing company. Secondary antibodies were diluted 5,000-fold. 
 
Primary antibody  Isotype  Distributor 
α - Acly    Rabbit  Abcam, Cambridge, UK 
α - ApoB    Mouse  Santa Cruz, Heidelberg 
α - Flag    Mouse  Sigma, Munich 
α - Lipin1    Rabbit  Abcam, Cambridge, UK  
α - Myc    Mouse  Upstate, Schwalbach 
α - TBL1    Rabbit  Abcam, Cambridge, UK 
α - TBLR1    Rabbit  Imgenex, San Diego, USA 
α - TSC22D4    Mouse  Abcam, Cambridge, UK 
α - VCP    Mouse  Abcam, Cambridge, UK 
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Secondary antibody  Isotype  Distributor 
α - Mouse IgG, HRP  Goat   BioRad, Munich 
α - Rabbit IgG, HRP  Goat   BioRad, Munich 
α - Goat IgG, HRP   Rabbit  BioRad, Munich 
 
Oligonucleotides 
All oligonucleotides possessed a G/C content between 40% and 60% and were 
approximately 20-30 bp in length.  
 
Restriction sites for specific enzymes were added to the cloning primers in 5’→3’ 
orientation, allowing directed insertion into a specific target vector. Six thymidine 
residues were added to the 5’ ends of the restriction sites in order to facilitate 
cleavage. The primers were designed to hybridize at temperatures of approximately 
56°C. 
 
Molecular weight markers 
DNA marker   Range  Distributor  
Gene RulerTM 1kb DNA ladder 250 – 10,000 bp Fermentas, St. Leon-Rot 
 
Protein marker   Range  Disributor 
Prestained Protein Ladder  10 – 180 kDa Fermentas, St. Leon-Rot 
Unstained Protein Ladder  10 – 200 kDa Fermentas, St. Leon-Rot 
 
 
7.8 Cell lines 
 
 
Bacterial cell lines  
Cell line       Distributor 
E.coli BL21 Chemically Competent Cells  Stratagene, La Jolla, USA 
E.coli SURE2® Chemically Competent Cells  Qiagen, Hilden 
E.coli TOP 10 Chemically Competent Cells  Invitrogen, Karlsruhe 
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E.coli XL1-Blue cells were obtained from Stratagene, La Jolla, USA and were used to 
produce chemically competent cells. 
 
Eucaryotic cell lines  
Cell line       Distributor 
HEK 293 human embryonic kidney cell line  ATTC, Wesel 
HEK 293-T human embryonic kidney cell line   ATTC, Wesel 
HEK 293-A human embryonic kidney cell line   ATTC, Wesel 
Hepa1c1 mouse hepatoma cell line   ATTC, Wesel 
 
 
7.9 Software 
 
 
Software       Distributor 
BLAST       http://www.ncbi.nlm.nih.gov 
Endnote       Thomson, Carlsbad, USA 
Microsoft Office      Microsoft, Unterschleißheim 
Mikro Win       Mikrothek, Overath 
Photoshop       Adobe, San Jose, USA 
Pubmed       NIH 
Quantity One      Bio-Rad, Munich 
Vector NTI Advance™ Software    Invitrogen, Karlsruhe 
Genious Software      Biomatters Ltd., Auckland, NZ 
 
METHODS 
 
87 
 
8. METHODS 
 
8.1 Molecular Biology 
 
 
8.1.1. Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to analyze PCR products, and digested 
plasmids. 1-3 % agarose was dissolved in TBE buffer and brought to the boil. Upon 
cooling, 0.5 µg/mL ethidium bromide was added. Gels were run at 100 V with 
constant current.  
 
8.1.2. Extraction of DNA from agarose gels 
 
DNA fragments were excised from agarose gels under a UV lamp using a skalpel and 
purified using the QIAquick Gel Extraction Kit, according to the manufacturer’s 
instructions. 
 
8.1.3. Restriction analysis of DNA fragments or plasmids 
 
For restriction analysis DNA was incubated with 10-20 units of restriction enzyme 
(New England Biolabs) per µg (based on DNA concentration) and 1 μL of 10X 
reaction buffer. Reactions were incubated at 37°C for 2-4 hours. 
 
8.1.4. Polymerase chain reaction (PCR) 
 
PCR was performed to amplify DNA fragments using a heat stable DNA polymerase. 
A typical reaction scheme is shown below. 
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Amount  Final concentration 
5X Phusion polymerase buffer      10 μL   1 X 
10 mM dNTP mix      1 μL   0.2 mM 
Forward primer (100 μM )    1μL   2 μM 
Reverse primer (100 μM)     1 μL   2 μM 
DNA Template      ~ 5 ng 
Phusion polymerase    1 μL   2 U  
Double distilled water     ad 50 μL 
A typical PCR reaction was programmed as follows: 
 
Step     Temperature   Time 
1. Denaturation   95°C     30 sec 
2. Denaturation  95°C     10 sec 
3. Primer annealing  55 – 65°C   30 sec 
4. Extension    72°C     60 sec 
5. Go to 2       30x 
6. Extension    72°C     5 min 
7. Hold    4°C     ∞ 
 
The annealing temperature was adjusted depending on the length and G/C content of 
the primers using the following formula: (TAn=69°C + 0.41 x (%GC) – 650 / bp). 
 
8.1.5. Ligation 
 
Ligation reactions were performed in 20 µl volume. 50-200 ng of vector were used for 
each reaction and the molar ratio of insert to vector was adjusted to be 3:1. The DNA 
was mixed in a volume of 10 µl and incubated at 45°C for 5 min. Subsequently 
ligation buffer and T4 DNA ligase were added. Reactions were incubated at room 
temperature for 2-4 hours and stored at 4°C overnight. A reaction containing the 
vector alone was used as a negative control to determine the degree of vector self-
ligation. 
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8.1.6. Chemical transformation of Escherichia coli 
 
Competent cells were thawed on ice. 2-10 μl of ligation mix, or 0.1-1 µg of plasmid 
were added to the cells and incubated on ice for 20-30 min. Heat shock was applied 
by incubating the vials in a water bath at 42°C for 45 sec. 300 μl of LB medium were 
added to each tube and bacteria were incubated at 37°C in a table top shaker for 1 
hour. After incubation, 100-200 μL of cells were directly plated on LB-agar plates 
containing the appropriate antibiotic. Plates were incubated at 37°C overnight and 
then stored at 4°C. 
 
Small scale liquid cultures 
A single bacterial colony was used to inoculate 4 ml LB-medium containing the 
appropriate concentration of a specific antibiotic. Cultures were incubated overnight 
at 37°C under vigorous shaking and used for small scale DNA preparation (Mini 
Prep) the following morning. 
 
Large scale liquid cultures 
For large scale DNA preparation (Maxi Prep), 200 ml LB-medium containing the 
appropriate concentration of a specific antibiotic, were inoculated with either a 4 ml 
pre-culture or a single bacterial colony. Cultures were incubated overnight at 37°C 
under vigorous shaking. 
 
8.1.7. Plasmid preparation 
 
Small scale plasmid preparation (Mini Prep) 
Plasmid preparation from small scale bacterial liquid cultures was performed using 
the Qiaprep Plasmid Miniprep Kit provided by Qiagen. The specifications given in the 
distributor’s protocol were followed and the DNA was eluted with 50 µl elution buffer 
(provided with the kit). Plasmid DNA was stored at -20°C. 
 
Large scale plasmid preparation (Maxi Prep) 
Plasmid preparation from large scale bacterial liquid cultures was performed using 
the Invitrogen Maxiprep Kit. The plasmid DNA was resuspended in 200 µl H2O and 
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the concentration was determined by spectral photometry. Plasmid DNA was stored 
at -20°C. 
 
8.1.8. DNA sequencing 
 
Plasmids were sequenced by the company AGOWA (Berlin). 
  
8.1.9. RNA isolation from tissue samples 
 
10-30 mg of frozen tissue were transferred into a 2 ml RNase/DNase-free reaction 
tube containing 1 ml of Qiazol™ Lysis reagent and a stainless steel bead. The samples 
were lysed using the TissueLyser™ for 90 sec and at a frequency of 30 Hz. Lysates 
were incubated at room temperature for 5 min to release nucleoprotein complexes 
before they were transferred into a fresh 1.5 ml RNase/ DNase-free safe-lock tube 
containing 200 µl of chloroform. Mixtures were vortexed for 15 sec and then 
centrifuged for 20 min at 13,000 rpm. The upper aqueous solution, containing the 
RNA, was carefully transferred into a fresh reaction tube. The RNA phase was then 
mixed with 500 µl of iso-propanol and incubated at room temperature for 10 min, 
followed by a 10 min centrifugation step at 12,000 rpm. The supernatant was 
aspirated and the pellet was washed once with 1 ml of 75% ethanol. The solvent was 
discarded, and the remaining ethanol was removed using a pipette. The pellet was 
briefly air-dried and re-solubilised in water (30-50 µl). To increase solubilisation, the 
RNA solution was incubated at 55-60°C for 10 min. The samples were stored at -80°C 
until further use. 
 
8.1.10. RNA isolation from cell samples 
 
Adherent cells were treated according to experimental needs. The medium was 
removed and the cell monolayer was washed once with sterile PBS. The buffer was 
aspirated and 1 mL Qiazol™ Lysis reagent was added per plate or well. The cells were 
released from the plate using a pipette and transferred into DNase/RNase-free 
reaction tubes, in which they were incubated for 5 min at room temperature. The 
samples were vortexed vigorously, until all cells were solubilised. The obtained cell 
METHODS 
 
91 
 
lysates were stored at -80°C or immediately used for RNA isolation, as described 
above. 
 
8.1.11. RNA isolation using the RNeasy Mini purification kit 
 
For microarray analysis, RNA isolated using Qiazol™ Lysis reagent was purified 
using the RNeasy Mini purification kit. RNA samples were diluted in 350 µl of RW1 
buffer, transferred to RNeasy columns and centrifuged at 12,000 rpm for 1 min. The 
flow-through was discarded and the columns were washed with 350 µl RW1 buffer for 
5 min. The buffer was removed by centrifugation. 80 µl of buffer, containing 10 µl 
DNase and 70 µl RDD buffer were added directly. DNA digestion was performed for 
30 min at room temperature. Subsequently, 350 µl RW1 buffer was added and the 
samples were incubated for another 2 min. Columns were washed twice with 500 µl 
RPE buffer. Finally, the RNA was eluted in 30 µl RNase free water. 
 
8.1.12. cDNA synthesis 
 
1-3 µg of purified RNA were used for cDNA synthesis. The reaction volume was 
adjusted to 9 µl per sample using RNase/DNase-free water. 1 µl of oligo(dT)18 
primers were added. Reactions were vortexed and incubated at 70°C for 5 min, to 
allow the primers to anneal to the poly-A tails. A mix, containing 4 µl 5 x reaction 
buffer, 2 µl 10 mM dNTP mix and 1 µl Ribolock™ Ribonuclease Inhibitor was then 
prepared. This reaction mixture was added to the samples and incubated for 5 min at 
37°C. Subsequently, 2 µl M-MuLV reverse transcriptase (RT) were added. To assess 
potential DNA contamination of reagents, an additional reaction was performed 
without reverse transcriptase. After 1 hour incubation at 37°C, samples were 
incubated at 70°C for 10 min to inactivate the reverse transcriptase and terminate 
cDNA synthesis. After completion, cDNA was stored at -20°. 
 
8.1.13. Quantitative Real-Time PCR 
 
cDNA samples were diluted ten-fold with DNase/RNase free water. 5 µl of this 
mixture were then used for each real time PCR reaction. A reaction sample mix 
consisting of 10 µl Platinum® Quantitative PCR Supermix, 4.5 µl DNase/RNase free 
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Water and 0.5 µl Taqman probe was added to each individual reaction. All probes 
were obtained from Applied Biosystems or MWG. Water was used as a negative 
control and samples containing no reverse transcriptase served as controls for 
genomic DNA contamination. The PCR reaction mix was transferred to a 
MicroAmp™ Optical 96-well reaction plate. All reactions were performed in technical 
duplicates. Quantitative PCR was performed using a 7,300 Real Time PCR System 
(Applied Biosystems). 
 
8.1.14. Gene expression profiling 
 
Gene expression profiling was performed with RNA extracted from livers of TSC22D4 
shRNA, TBL1/TBLR1 shRNA or control virus injected mice. RNA isolation, cRNA 
synthesis and hybridization to Mouse Genome 430 2.0 arrays from Affymetrix were 
performed according to the manufacturer’s recommendations. Three arrays per 
genotype were hybridized with pooled RNA samples (2-3 animals per array total 
n=7). Microarray data were analyzed based on ANOVA using a commercial software 
package (Micro Array Solution, version 1.0; SAS Institute, Cary, NC). Standard 
settings were used, except for the following specifications: log-linear mixed models 
were fitted for values of perfect matches, with genotype considered to be constant and 
the array identification, random. Custom CDF with Unigene-based gene / transcript 
definitions was used to annotate the arrays. Affected biological pathways ( [including 
KEGG]) reflected by the differential gene expression were determined by ORA based 
on Fisher exact test.  
 
 
8.2 Cell Biology 
 
 
8.2.1. Cultivation of Human Embryonic Kidney (HEK), HEK293A and 
HEK293T cells 
 
HEK 293 cells were maintained and propagated in Dulbecco’s Modified Eagle 
Medium with high glucose (DMEM), 10 % fetal calf serum (FCS) and 1 % penicillin/ 
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streptomycin. HEK293A and HEK293T cells also required 1 % Non-Essential Amino 
Acids (NAA). Cells were split by the factor 1:20 two times per week. 
 
8.2.2. Cultivation of Hepa1c1 mouse hepatoma cells 
 
Hepa1c1 cells were maintained and propagated in MEM (Minimal Essential Medium) 
medium containing 10 % FCS, 1 % penicillin / streptomycin and 1% NAA. Cells were 
split by the factor 1:10 two times per week 
 
8.2.3. Cell culture and transient transfection assays 
 
Experiments involving eukaryotic cells were performed under sterile conditions. 
Media and reagents were preheated to 37°C prior to use. All cells were cultivated at 
37°C, 5% CO2 and 95% humidity in 6-well, 12-well, 10 cm or 15 cm cell culture dishes. 
Human HEK293 cells and murine Hepa1c1 hepatocytes were transfected using 
Lipofectamine or polyethylenimine (PEI) reagent, a substance with low cytotoxicity.  
 
Luciferase assays 
Hepa1c1 cells were plated on 6-well plates at a concentration of 5 x 105 cells / well the 
day before the experiment. The amount of PEI was calculated with respect to the 
amount of DNA that was used for the individual transfection. Generally, 8 µl of PEI 
were applied per µg of DNA. A reaction was prepared containing DNA, PEI and 
1500µM NaCl and incubated at room temperature for 10 min. This mixture was added 
to fresh medium containing 10% FCS, 1% P/S and 1% NAA. Cell extracts were 
prepared 48 hours after transfection. The medium was removed and cells were 
washed once with PBS. Harvest buffer was added and the samples were incubated on 
a shaker for 5 min to facilitate detachment from the dish. Next, cells were scratched 
from the plate. Lysates were transferred to 1.5 ml reaction tubes. For each well 150 µl 
of harvest buffer were used. Insoluble cell debris was removed by centrifugation for 3 
min at 13,000 rpm and the supernatants were transferred to a fresh tube. The lysates 
were used directly for reporter gene assays or stored at -20°C. Luciferase is an 
enzyme that catalyses a reaction in which luciferin is transformed into oxyluciferin by 
oxidative decarboxylation, thereby emitting photons. Under assay conditions the 
substrate luciferin is available in excess, consequently the amount of light emitted is 
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proportional to the amount of luciferase in the lysate. To determine luciferase activity 
in lysates, 30 µl of lysate were transferred into a well on a black 96-well-plate. Lysates 
were complemented with 100 µl assay buffer and plates were measured using a 
luminometer (Mithras 940 Luminescence) equipped with a dispenser. Automatic 
injection of 100 µl luciferin buffer started the reaction. Light emission was measured 
at a wavelength of 560 nm and harvest buffer alone was used to determine a blank 
value. All results were normalized to the activity resulting from a co-transfected β-
galactosidase expression plasmid harbouring an H-Ras promoter (H-RAS β-Gal). For 
the assay a buffer containing the substrate ortho-nitrophenyl-β-galactopyranosid 
(ONPG) was prepared. 5 ml of this buffer were mixed with 13.5 µl beta-
mercaptoethanol prior to the β-gal assay. 50 µl cell lysate / well were transfered into a 
clear 96-well plate and 50 µl ONPG buffer were added to each well. Harvest buffer 
was used to obtain a blank value. The plates were incubated at 37°C for 6-12 hours 
until a clear yellow colour was visible. The absorption was measured at 405 nm, the 
maximum absorption of the ortho-nitrophenylat ion. The values were analysed with 
respect to the noise signal and used to normalise the luciferase signals. 
 
8.2.4. Primary hepatocyte experiments 
 
Primary mouse hepatocytes were isolated and cultured as described (124). Male 8-12 
week old C57Bl/6J mice were anesthetized by intraperitoneal injection of 5 mg 10% 
ketamine hydrochloride / 100 mg body weight and 1 mg 2% xylazine hydrochloride / 
100 mg body weight. After opening the abdominal cavity, the liver was perfused with 
HANKS I buffer via the portal vein for 5 min at 37°C and subsequently with HANKS 
II buffer for 5-7 min until disintegration of the liver structure could be observed. The 
liver capsule was removed and the cell suspension was filtered through a 100 µm 
mesh. Cells were washed and, subsequently, viability of cells was determined by 
trypan blue staining. 500,000 living cells / well were seeded on collagen I-coated 6- 
or 12-well plates. Cells were infected with recombinant adenoviruses (multiplicity of 
infection = 100) 24 hours after seeding and harvested for mRNA analysis 48 hours 
later.  
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8.3 Animal experiments 
 
 
8.3.1. General procedures 
 
Male 8-12 week old C57BL/6J or Balb C mice were obtained from Charles River 
Laboratories (Brussels, BEL) and maintained on a 12 hour light-dark cycle with 
regular unrestricted diet and free access to water. For fasting experiments, animals 
were fasted for 16 hours. For adenovirus injections, 1-3 x109 plaque-forming units per 
recombinant virus were administered via tail vein injection. In each experiment, 5-8 
animals received identical treatments and were analyzed under fasted, control fed or 
random fed conditions as indicated. In high-fat diet experiments, C57BL/6J mice 
were injected with 5x 1011 AAV particles per mouse and fed a high-fat diet (60% 
energy from fat, Research diets D12492) for a period of 9-11 weeks. In methionine 
/choline deficiency studies, mice were fed the MCD diet for 4 weeks (Research diets). 
In C26 experiments, 1.5x 106 colon tumour cells were injected subcutaneously into 
BalbC mice. Organs including liver, kidney, epididymal fat pads, and gastrocnemius 
muscles were collected after the corresponding time periods, weighed, snap-frozen 
and used for further analysis. Total body fat content was determined using an Echo 
MRI body composition analyzer. Animal handling and experimentation was 
performed in accordance with NIH guidelines and approved by local authorities. 
 
8.3.2. Hepatic VLDL release 
 
VLDL production was determined after tyloxapol injection as described (78). 
Tyloxapol is a Lipoprotein Lipase (LPL) inhibitor, meaning that, after administration, 
any secreted VLDL particles could not be cleared from the blood stream. One day 
before the experiment, tyloxapol was dissolved in saline to obtain a 20% w/v solution. 
Six C57BL/6J mice per group were fasted overnight for 16 hours. On the following 
day, before administration, 40µl of blood was drawn from each mouse by cutting the 
tip of the tail. The tyloxapol (20%) volume (in µl) applied per mouse was approx. 3 
times that of the weight of the mouse in grams; i.e. a 25 g mouse received 75 µL of the 
20% solution. Specified amounts were administered via the tail vein and 40 µL blood 
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samples were taken every 50 min for 2.5 hours. The mice were sacrificed after 300 
min. The serum TG values were determined and plotted against the time. 
 
8.3.3. VLDL clearance 
 
Blood was drawn from a fasted individual and human VLDL was isolated by 
ultracentrifugation as described (125). 3.5 ml serum were put in a polyallomer tube 
(SW40Ti) and mixed with 1.39 g KBr, over-layered with 3x2.8 ml of a NaCl/KBr 
solution (D= 1.063, 1.019 and 1.006 g/ml) and run for 18 hours at 40,000 rpm. 20 µg 
of human VLDL were injected into each animal and serum samples were taken at 2, 
10, 30, 60 and 120 min. Human ApoB-100 levels were measured using a human-
specific ApoB ELISA. For the ELISA, a primary coating antibody generated against 
human ApoB-100 (mAb47, kindly supplied by J. Witztum, University of San Diego, 
USA), at a concentration of 2 µg/well and a secondary biotinylated polyclonal 
antibody raised in goat against human ApoB at a concentration of 4 µg/well in 1.5% 
BSA/TBS/0.1% tween were used. To prevent non-specific binding, plates were 
blocked with 1.5% BSA/TBS/0.1% tween. Samples were diluted 25-fold. Absorbance 
was read 30 min after addition of TMB and termination of the reaction with 2 M 
H2SO4 at 450 nm (126).  
 
8.3.4. Intravenous lipid load test 
 
Intralipid (20 % fat emulsion) was obtained from Sigma. Seven mice per group were 
fasted overnight for 16 hours. The following day mice were injected with 100 µL of 
intralipid solution. 30 µL of blood was collected prior to injection and at 2, 10, 20, 30, 
60 and 120 min time points. Serum was isolated and used for determination of TG 
content. The TG values were determined and plotted against the time. 
 
8.3.5. Glucose tolerance test 
 
In a glucose tolerance test, glucose is injected in the peritoneum of fasted mice and 
blood samples are taken to determine how quickly the sugar can be cleared from the 
blood. Improved insulin signaling results in lower glucose levels as the sugar load 
induces a better clearance from the blood stream. Mice were fasted for 16 hours prior 
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to the experiment. The animals were transferred into fresh cages equipped with fresh 
water but no food. The following morning, the body weight and the initial blood 
glucose levels were determined by nicking the tail with a razor blade. Blood glucose 
was measured using a glucometer strip. 10 µl/g body weight of a 20% glucose 
solution were then injected intraperitoneally. Blood glucose was meassured 10, 20, 
30, 60, 90 and 120 min after injection.  
 
8.3.6. Insulin tolerance test 
 
An insulin tolerance test (ITT) is a procedure in which insulin is injected into a mouse 
to assess if it can still induce its full function. If mice are insulin resistant, blood 
glucose levels are elevated over time. For the insulin tolerance test a stock solution of 
0.75 U insulin/ml was prepared using 0.9% sodium chloride. The body weight of all 
animals was determined and the blood glucose levels were measured by cutting the 
tail with a razor blade. The blood drop was put onto a glucometer strip and measured.  
1 U insulin/kg body weight was injected intraperitoneally. The blood glucose levels 
were monitored after 10, 20, 30, 60 and 120 min.  
 
8.3.7. Acute insulin signalling 
 
To analyze the acute effects of insulin administration, mice were injected with 1U/kg 
insulin or PBS and sacrificed precisely 10 min later. Organs were quickly removed 
and insulin signalling was analyzed by Western blot. 
 
 
8.4 Biochemistry 
 
 
8.4.1. Luminescence-based mammalian interactome mapping (LUMIER)  
 
The LUMIER screen was used to find novel TBL1 and TBLR1 interaction partners. 
Proteins were transiently expressed in HEK293 cells as hybrid proteins with the 
Staphylococcus aureus protein A tag or Renilla reniformis luciferase fused to their 
amino termini. 20 ng of each expression construct were transfected into 10,000 
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HEK293 cells using 0.05 µl of lipofectamine 2,000 in 96 well plates. After 40 hours, 
medium was removed and cells were lysed on ice in 10 µl of ice-cold lysis buffer (20 
mM Tris pH 7.5, 250 mM NaCl, 1% TritonX-100, 10 mM EDTA, 10 mM DTT, 
Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail, Benzonase containing 
sheep-anti-rabbit IgG-coated magnetic beads (Invitrogen, Dynabeads M280, 2 
mg/ml final concentration). Lysates were incubated on ice for 15 min. 100 µl of 
washing buffer (PBS, 1 mM DTT) were added per well, and 10% of the diluted lysate 
was removed to determine the luciferase activity present in each sample before 
washing. The rest of the sample was washed 6 times in washing buffer in a Tecan 
Hydroflex plate washer. Luciferase activity was measured in the lysate as well as in 
washed beads. Negative controls were wells transfected with the plasmid expressing 
the luciferase fusion protein and a vector expressing a protein A dimer. For each 
sample, four values were measured: the luciferase present in 10% of the sample 
before washing (“input”), the luciferase activity present on the beads after washing 
(“bound”), and the same values for the negative controls (“input nc”, and “”bound 
nc”). Normalised interaction signal to noise ratios were calculated. 
 
8.4.2. Preparation of protein extracts from liver samples  
 
For protein extractions, 2 ml reaction tubes were filled with 1 ml lysis buffer, protease 
inhibitors and a stainless steel bead. 
 
Lysis buffer:        
50 mM Tris, pH 7.2     
1 mM EDTA     
10 mM NaF      
2 mM Na3VO4      
1 mM DTT      
1 x PIC      
 
Approximately 50 mg of frozen liver tissue were transferred into the ice-cold buffer 
and the sample was immediately homogenized using the Tissue Lyser for 2 min at 30 
Hz. The extracts were incubated on a rotating wheel for 1 hour and then 
supplemented with high salt denaturation buffer and incubated for an additional 
hour on the wheel at 4°C. The lysates were transferred to fresh tubes and the protein 
concentration was determined. Samples were adjusted to a concentration of 1 mg/ml 
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protein with 2 x SDS buffer and incubated at 95°C for 7 min to denature proteins. 
Afterwards they were either stored at -20°C, or used directly for SDS-PAGE and 
immunoblotting.  
 
8.4.3. SDS-PAGE analysis and immunoblotting 
 
20 µg of protein/well were loaded onto 4–12 % SDS-polyacrylamide gels and blotted 
onto nitrocellulose membranes using a wet blot system. Blotting was performed at 
80V for 2 hours or 30V overnight in transfer buffer. Membranes were subsequently 
blocked by incubtation in 5% milk or 5% BSA dissolved in PBS/T for 1 hour. Specific 
primary antibodies diluted in milk or BSA, according to the manufactures 
recommendations, were incubated with the membranes for 1 hour at room 
temperature or overnight at 4°C. The membranes were washed with PBS/T the next 
day and incubated with the secondary antibody conjugated to horse radish 
peroxidase (HRP) at a dilution of 1:10,000 for 1 hour. To detect specific bands the 
enhanced chemiluminescence system (ECLTM) Western Blotting Detection Reagent 
was applied. Hyperfilm ECL films were exposed to the chemiluminescent signal 
produced by the blots. Exposure times differed based on the quality of specific 
antibodies. 
 
8.4.4. Determination of free fatty acid levels 
 
Free Fatty Acids were determined in serum samples using a colorimetric assay from 
Wako. The assay principle is based on the following three reactions, whereby R-
COOH represents any free non esterified carbonic acid: 
 
1) RCOOH + ATP + CoA-SH → Acyl-CoA + AMP + PPi (Enzyme: acyl CoA 
synthetase) 
2) Acyl-CoA + O2 → 2,3-Enoyl-CoA + H2O2 (Enzyme: acyl CoA oxidase) 
3) H2O2 + 4-Aminophenazon + 3-methy-N-ethyl-N(β-hydroxyethyl)-aniline → 
Quinoneimine-color + 4 H2O (Enzyme: peroxidise) 
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A standard curve was determined using a dilution series of oleic acid. The procedure 
was carried out according to the manufacturer’s instructions. OD-values were 
determined at 540 nm. 
 
8.4.5. Serum ketone body measurement 
 
Total serum ketone bodies were determined using a commercial kit (Autokit Total 
Ketone Bodies, Wako chemicals GmbH). The assay is based on an enzymatic reaction 
where the rate of Thio-NADH production depends on the concentration of total 
ketone bodies in the sample and can be determined using a photometer. A standard 
curve was prepared by serially diluting the calibrator provided in the kit. 4 µl were 
used for measurements and absorbance was measured at 405 nm. 
 
8.4.6. Isolation of hepatic lipids 
 
Lipids were extracted from frozen liver tissue using chloroform/methanol (2:1 v/v). 
About 100 mg (the exact weight was noted) of frozen, pulverized liver were 
transferred into a 2 ml polypropylene tube containing 1.5 ml chloroform/methanol 
and a steel bead. The tissue was homogenized using a tissue lyzer for 1 min at a 
frequency of 30 Hz. For the lipid extraction, samples were incubated on a rotating 
wheel at room temperature for 20 min. Reactions were centrifuged at 4,000 rpm for 
10 min and supernatants were transferred to fresh tubes. The organic layer was 
mixed with 0.9% sodium chloride and the aqueous solution was carefully discarded. 
50 µl of the organic layer were transferred to a fresh tube and 10 µl of Triton-X 100/ 
chloroform (1:1 v/v) were added. The reagents were mixed and the solvent was 
evaporated. The residue containing the hydrophobic contents of the liver was 
resuspended in 50 µl water and stored at -20°C until further use.  
 
8.4.7. Determination of triglyceride levels 
 
TG levels were determined by separating TGs into one glycerol and three fatty acid 
molecules and measuring the glycerol using a colorimetric assay. The serum TG 
determination kit from Sigma was used for this assay. 4 µL of isolated hepatic TGs or 
4 µL of serum were transferred to a 96-well plate. In order to determine a blank 
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value, 100 µl Free Glycerol Reagent were added to each well and the plate was 
incubated at 37°C for 5 min. Free glycerol levels were measured at 540 nm. In a 
second reaction (assay), 100 µl TG Reagent were added. This mixture contains the 
enzyme lipase, which catalyses the release of fatty acids from TGs. Plates were 
incubated at 37°C for 5 min and measured at 540 nm. TG content was determined by 
subtracting the free glycerol (blank) from the second measurement (assay). 
 
8.4.8. Cholesterol measurement 
 
Liver or serum cholesterol concentrations were determined using a total cholesterol 
determination kit (Randox Laboratories). The assay is based on the following 
reactions:  
1) Cholesterol → Cholesten-3-on +H2O2 (Enzyme: cholesteroloxidase)   
2) 2H2O2 + Phenol + 4-Aminoantipyrin → Chinonimin + 4 H2O (Enzyme: 
peroxidase) 
 
4 µl of each sample were mixed with 100µl assay reagent and incubated at 37°C for 5 
min. The optical density was measured at 492 nm and the sample concentration was 
determined using a standard curve resulting from a serial dilution of cholesterol 
(200mg/dL; provided with the kit). 
 
8.4.9. Blood glucose measurements 
 
Serum glucose levels were determined using a drop of blood obtained from the tail 
vein and an automatic glucose monitor (One Touch, Lifescan). 
 
8.4.10. Insulin measurement 
 
Insulin levels were determined using an ELISA kit (Mercodia). Plates containing the 
insulin antibody were provided and were activated using a buffer contained in the kit. 
5 µl of each sample or standard (provided in the kit) were added to each well. Plates 
were then incubated at 4°C for 2 hours. Plates were washed five times in the provided 
buffer and 100 µl of anti-insulin conjugate were added to each well. Reactions were 
incubated at room temperature for a further 30 min and then washed several times. 
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100 µl of enzyme substrate solution were added to each well and the plates were 
incubated at room temperature for 40 min. Reactions were stopped by adding 100 µl 
of stop solution to each well and measuring the absorbance at 450 nm. Insulin 
concentrations were determined using a standard curve resulting from a serial 
dilution of insulin. 
  
8.4.11. LPL activity 
 
5 ml cold acetone were added to frozen white adipose tissue samples (50 mg) and 
homogenized. The precipitate was separated from the organic phase and washed with 
cold diethyl ether. LPL was reconstituted and the obtained protein was centrifuged at 
12,500 g and 5°C for 10 min and LPL activity was measured in the supernatant, by 
assessing the release rate of of [14C] oleate from glyceryl tri- [14C] oleate. The precise 
protocol is described (127). 
 
8.4.12. Fast protein liquid chromatography (FPLC) 
 
FPLC was used to separate serum proteins according to their size. The FPLC set-up 
consisted of a Superose 6 10/300 GL column (GE Healthcare), a fraction collector 
and an ÄKTA FPLC System (Amersham). During separation, a liquid phase, 
containing the mixture to be fractionated was pumped over a stationary resin of 
cross-linked agarose beads with varying surface structure. Certain proteins 
subsequently eluted at specific times in specific fractions. A pool of 250-300 µl 
serum, from 4-8 animals, was injected into the machine, diluted in 25 ml PBS and 
fractionated into 500 µl fractions. 40 µl of each fraction were subsequently used for 
cholesterol and TG analysis using the TG Liquicolor (Human GmbH, Germany) and 
Cholesterol determination kit (Randox, UK) respectively. Distinct VLDL and HDL 
peaks could be observed in specific fractions (128). 
 
8.4.13. Co-Immunoprecipitation 
 
Hepa 1c1 cells were cotransfected with a Flag-TBL1, Flag-TBLR1 or an empty Flag 
vector in combination with a Myc-TSC22D4 vector. Subsequently, cells were lysed 
and centrifuged. The supernatant was incubated with anti-FLAG M2 Agarose for 2 
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hours and washed vigorously to remove unspecific binding. Precipitated proteins 
were eluted using excess Flag peptide. The immunoprecipitates were subsequently 
analyzed by Western blot as described. The same protocol was applied to 4 mg of 
pulverized liver extracts transduced with Flag-TSC22D4. 
 
8.4.14. GST-Pulldown 
 
GST-pulldown experiments were performed to assess whether TSC22D4 binds 
directly to TBL1 and TBLR1 and, if so, to map the interaction. One protein partner is 
purified from bacteria using a GST-tag and the second protein is in vitro transcribed 
and translated in the presence of radiolabeled methionine. Full length and truncated 
GST fusion proteins were produced in BL21 cells and affinity purified using 
glutathione sepharose. In vitro transcription/translation was performed using the 
TNT T7/T3 quick coupled transcription/translation system according to the 
manufacturer's instructions. GST and in vitro translated full length and truncated 
proteins were incubated at 4°C overnight. After extensive washing, GST-precipitated 
proteins were separated by SDS-PAGE and detected by autoradiography as described 
(129). 
 
8.4.15. Histochemistry (Hemotoxylin and Oil red O).  
 
During preparation of liver tissue, slices were embedded Tissue Tek OCT compound 
and shock frozen in liquid nitrogen. 5 µm cryosections were cut and fixed in Baker’s 
formol. Neutral lipids and TGs were stained with oil red O and nuclei were 
counterstained with hematoxylin. 
 
8.4.16. Plasmids and RNA interference 
 
shRNAs targeting mouse TSC22D4 (5'-GCCTGGTTGGCATTGACAACACGAATG-3')  
TBL1 (5'-GCGAGGATATGGAACCTTAAT-3'), TBLR1 (5’-
GCATAAAGGTCCTATATTTGC-3’) or non specific oligonucleotides (5’-
GATCTGATCGACACTGTAATG-3’)  were cloned into the pENTRY RNAi vector 
(Invitrogen, Karlsruhe, DEU) and used in adenovirus and transient transfection 
experiments. miRNAs targeting TSC22D4 (5'-ACCACTATCGTCATCGCTGTC-3') or 
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unspecific miRNAs (5'-AAATGTACTGCGCGTGGAGAC-3') were used in adeno-
associated virus experiments. The FasN-Luc reporter plasmid was kindly provided by 
Timothy Osborne (UCI). Expression vectors for TSC22D4, TBL1 and TBLR1 were 
generated by standard PCR-based methods and cloned into the pcDNA3.1 expression 
vector. 
 
 
8.5 Virology 
 
 
8.5.1. Cloning of adenoviruses 
 
The BLOCKiT™ Adenoviral RNAi Expression System was used to generate 
adenoviruses expressing shRNA sequences against murine TSC22D4, TBL1 and 
TBLR1, as well non-specific shRNAs. Oligonucleotide sequences were chosen using 
Invitrogen’s RNAi Designer tool. Forward and reverse oligonucleotides against the 
target gene sequence were annealed and cloned into the pENTR™/U6 vector 
according to the manufacturer’s instructions. The resulting constructs were 
recombined with the pAd/BLOCK-iT™ DEST vector, which contains the adenovirus 
serotyp 5 DNA, but lacks the E1 and E3 genes that are required for viral replication. 
The viral vector containing the shRNA sequence was linearized by restriction digest 
using the enzyme PacI and transfected into HEK 239A cells using Lipofectamine 
reagent according to the manufacturer’s instructions. HEK293A cells express the 
viral E1 and E3 genes necessary for viral outbreak, allowing the virus to expand in 
this cell line. Viral plaques appeared 6 to 10 days after transfection and cells started 
to detach from the cell culture dish. Once about 70% of cells were floating, they were 
harvested. The same procedure was used to generate viruses overexpressing 
TSC22D4. The TSC22D4 cDNA was cloned into a pENTR vector harbouring the CMV 
promoter and subsequently recombined with the pAd/BLOCK-iT™ DEST vector. An 
empty adenovirus was used as a negative control in over expression experiments. 
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8.5.2. Virus harvest using the Freeze-and-Thaw-method 
 
Cells infected with adenovirus were harvested in the medium they were cultivated in. 
The medium was collected from up to twenty 15 cm culture dishes and centrifuged for 
at 2,000 rpm for 10 min. The supernatant was discarded and the cell pellet was 
resuspended in 4 ml PBS-TOSH buffer. The tubes containing the virus were frozen in 
liquid nitrogen and subsequently thawed by vortexing. This freeze-thaw cycle was 
repeated three times and was required to release virus from the cells. After cell lysis 
the mixture was centrifuged at 2,000 rpm at 4°C for 10 min. The crude supernatant 
was stored at -80°C or directly used for applied to a caesium chloride gradient. 
 
8.5.3. Caesium chloride gradient 
 
Virus lysates from twenty 15 cm culture dishes were thawed on ice. PBS-TOSH was 
added to a final volume of 20 ml. Gradients were prepared in ultracentrifuge tubes 
(Beckmann Polyallomer 25mm x 89 mm) and were balanced after addition of each 
solution. First, 9 ml 4 M caesium chloride were added to the tubes, then 9 ml of 2.2 M 
caesium chloride were added and finally the viral lysate was carefully pipetted on top, 
creating three distinct layers. The gradients were centrifuged at 4°C and 24,000 rpm 
in a Beckmann ultracentrifuge XL-70 for 2 hours using a SW28 swing bucket rotor. 
After centrifugation a distinct band representing the purified adenovirus was visible 
between the 4 M and 2.2 M caesium chloride layers. The band was carefully removed 
by piercing the tube with a 5 ml syringe. The obtained virus (about 3 ml) was mixed 
with an equal volume of saturated caesium chloride solution and transferred into a 12 
mL centrifuge tube (Beckmann Polyallomer 14mm x 89 mm). 2 ml of the 4 M cesium 
chloride and 2 ml of the 2.2 M cesium chloride solution were used to overlay the 
gradient. The tubes were centrifuged at 4°C and 35,000 rpm in a SW41 Ti swing 
bucket rotor for 3 hours. A distinct viral band could be seen between the 4 M and 2.2 
M cesium chloride layers. The band (~ 700 µl) was removed using a 1 ml syringe. To 
remove cesium chloride from the viral solution, viruses were transferred to a dialysis 
membrane (Spectra/Por® Biotech, MWCO 15,000, 10 mm diameter) and dialyzed 
against 1 L PBS containing 10 % glycerol (v/v) 2 times (1 and 24 hours) at 4°C. After 
dialysis, aliquots of 20–100 μL were prepared and stored at -80°C until further use.  
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8.5.4. Virus titration 
 
The Tissue Culture Infectious Dose 50 (TCID50) assay was used to titrate adenovirus. 
HEK293A cells were harvested in DMEM medium containing 2% FCS (v/v), 1% 
penicillin/streptomycin and 1% non–essential amino acids and transferred to 96 well 
plates. 104 cells in a volume of 100 µl cells were added to each well and two plates 
(technical duplicates) were required for each titration. After seeding, cells were 
incubated for at least 4 hours, so that they could attach. In the mean time, serial 
dilutions of the viruses were prepared in the same medium as above. 100 µl of each 
dilution step (10-6–10-13) were added to ten wells and 100 µl of medium without virus 
were added to negative control wells. The cells were incubated for ten days, before 
they were used to determine the viral titer. Using a microscope, it was possible to 
detect plaque formation in the cell monolayer. Every well in which at least one plaque 
could be detected was considered a positive well. The titer was determined using the 
following formula:  
 
Ta= viruses per 100 µl =101+(s-0.5) 
s = the sum of all positive wells starting from the 10-1 dilution, whereby 10 
positive wells correspond to the value 1. 
T= viruses per 1ml = 10 x Ta 
 
8.5.5. AAV Production 
 
Adeno-associated viruses encoding TSC22D4-specific or non-specific control 
miRNAs were used for long-term inactivation of TSC22D4. The oligonucleotides were 
cloned into the pcDNA6.2-GW/EmGFP-miR vector and transferred into the 
previously described double stranded pdsAAV-LP1-EGFPmut AAV vector (63) using 
the restriction enzymes BglII and SalI. The plasmids encoding the miRNA constructs 
were contransfected into HEK293T cells with the pDGΔVP helper plasmid (130) and 
a mutated p5E18-VD2/8 expression vector (131) encoding AAV2 rep and a mutated 
AAV8 cap protein (aa 589-592: QNTA to GNRQ). For virus production, 3.85x 108 
cells were suspended in 1100 ml medium. 1,000 ml of the cell suspension was 
transferred to a 10x cell-stack chamber and 100 ml were transferred to a 1x-cell stack 
chamber (control chamber for analysis under the microscope). 24 h after plating, the 
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cells were approximately 70% confluent and were transfected with the plasmids 
encoding the viral genes using the PEI method in the amounts described below. 
 
  Plasmid     Amount 
  AAV-miRNA expression vector  436 µg 
p5E18 VD2/8 helper plasmid  550 µg 
pDG∆VP helper plasmid   1579 µg 
 
Once the cell monolayer was approximately 90% confluent, cells were washed with 
PBS, before they were released from the plate using 10 ml (1x cell stack) or 100 ml 
(10x cell stack) trypsin-EDTA for 5 min at 37°C. Fresh medium was added (40 ml or 
350 ml respectively) and the cells were transferred to a 50 ml falcon tube, or a 500 ml 
conical tube. The chambers were washed with PBS and used a second time. Cells were 
centrifuged at 2,000 rpm for 10 min. The supernatant was removed and the pellets 
were resuspended in 8 ml lysis-buffer containing 150 mM NaCl and 50 mM Tris-
HCL, pH 8.5. The lysates were transferred into 15 ml falcons, vortexed, snap-frozen 
in liquid nitrogen and stored at -80°C.  
 
8.5.6. AAV purification  
 
AAV lysates were thawed at 37°C under shaking and then centrifuged at 3,500 g for 
10 min. The supernatant was collected and the pellets were resuspended in 4 ml lysis 
buffer and snap-frozen. The freeze-thaw cycle was repeated three times. The final 
pellet was solubilised using a sonicator in a water bath at 48 W for 1 min. The pooled 
suspension was then digested with benzonase (50 U/ml) for 30 min at 37°C. This 
solution was then centrifuged at 4°C and 3,500 g for 10 min. The virus was stored at -
80°C until further use. 
 
1st Iodixanol gradient 
Purifying virus by iodixanol gradient leads to a separation of packed and unpacked 
AAV capsids, as they migrate differentially upon ultracentrifugation. The first 
gradient, ranging from 15% iodixanol to 40% iodixanol, was prepared on top of the 
viral solution in a Beckman Quickseal tube using a Pasteur pipette, as described 
below. 
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Layer (from top to bottom)  Component 
15 %-iodixanol dilution (7 ml)  1.75 ml OptiPrep 
       5.25 ml PBS-buffer 2 
25 %- iodixanol dilution (5 ml)  2.08 ml OptiPrep 
       2.29 ml PBS-buffer 1 
       12.5 µl phenol red (0.5 %) 
40 %- iodixanol dilution (4 ml)  2.67 ml OptiPrep 
       1.33 ml PBS-buffer 1 
60 %- iodixanol dilution (4 ml)  4 ml OptiPrep 
       10 µl phenol red (0.5 %) 
 Virus (18 ml) 
 
PBS-buffer 1: 1x PBS   PBS-buffer 2: 1x PBS 
    1 mM MgCl2     1 mM MgCl2 
    2.5 mM KCL     2.5 mM KCL 
          1 M NaCl 
 
About 1 ml of space was left above the gradient. Tubes were sealed and centrifuged in 
a 50.2 Ti rotor at 50,000 g and 10°C for 2 hours. Four gradients were run for each 
virus (two rounds; harvest and wash). After centrifugation, the 40% iodixanol layer 
(~3.5 ml) was carefully collected by inserting a 5 ml syringe from underneath. The 
viral suspension was pooled and stored at -80°C. 
 
2nd Iodixanol gradient 
The viral suspension resulting from the first gradient was filled up to 25 ml with lysis 
buffer. The second gradient was prepared by underlayering, as described below. 
 
Layer (from top to bottom)  Component 
25 %- iodixanol dilution (5 ml)  2.08 ml OptiPrep 
       2.29 ml PBS-buffer 1 
       12.5 µl phenol red (0.5 %) 
40 %- iodixanol dilution (4 ml)  2.67 ml OptiPrep 
       1.33 ml PBS-buffer 1 
METHODS 
 
109 
 
60 %- iodixanol dilution (4 ml)  4 ml OptiPrep 
       10 µl phenol red (0.5 %) 
 Virus (25 ml) 
 
PBS-buffer 1: 1x PBS   PBS-buffer 2: 1x PBS 
    1 mM MgCl2     1 mM MgCl2 
    2.5 mM KCL     2.5 mM KCL 
          1 M NaCl 
 
The gradient was then further processed as described for the first gradient.  
 
Virus concentration 
The viral solution was concentrated using a VivaSpin concentrator. The solution was 
consecutively centrifuged at 3,000 rpm and 10°C for 3-6 min. 
 
Virus titration 
Viral DNA was isolated by mixing 5 µl of virus suspension with 5 µl H2O and 10 µl 2M 
NaOH. The mixture was incubated at 56°C for 30 min and the reaction was then 
neutralized by adding 10 µl 2M HCL. After adding 970 µl H2O, the titer was 
determined by qPCR using an EGFP standard curve. 
 
 
8.6 Statistical Analysis 
 
 
Statistical analyses were performed using a 2-way analysis of variance (ANOVA) with 
Bonferroni-adjusted post-tests, or t-test in one-factorial designs, respectively. 
Correlation was determined using Pearson’s correlation coefficient. The significance 
level was at p = 0.05. 
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9. GLOSSARY 
 
AAV       Adeno-associated virus 
ApoB       Apolipoprotein B 
ATP       Adenosine triphosphate 
Acly       ATP-citrate lyase 
ß-gal        ß-galactosidase reporter 
BMI       Body mass index 
BSA        Bovine Serum Albumin 
cDNA       Complementary DNA 
CETP       Cholesteryl ester transfer protein 
CMV        Cytomegalovirus  
Dex        Dexamethasone 
DMEM       Dulbecco´s Modified Eagle´s Medium 
DNA        Desoxyribonucleic acid 
DTT       Dithiothreitol 
dNTP       Deoxyribonucleotide 
ER       Endoplasmatic reticulum 
EDTA       Ethylenediaminetetraacetic acid 
EGTA       Ethylene glycol tetraacetic acid 
ELISA      Enzyme-linked immunosorbent assay 
FCS       Fetal Calf Serum 
FPLC       Fast protein liquid chromatography 
GC       Gastrocnemius muscle 
GTT       Glucose tolerance test 
GST       Glutathione S-transferase 
HDAC      Histone deacetylase 
HDL       High density lipoprotein 
HEK        Human embryonic kidney cells 
HFD       High fat diet 
HRP        Horseradish Peroxidase 
HZ       Hertz 
ITT       Glucose tolerance test 
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LB        Luria-Bertani 
LDL       Low density lipoprotein 
LFD       Low fat diet 
Lpl       Lipoprotein lipase 
Luc        Luciferase Reporter 
LUMIER  Luminescence-based Mammalian 
Interactome mapping 
LXR       Liver X receptor 
Min       Minute 
miRNA       Micro RNA 
MOI        Multiplicity of infection 
MTP  Microsomal triglyceride transfer 
protein 
NAA       Non-essential amino acid 
NADH      Nicotinamide adenine dinucleotide 
NAFLD      Non-alcoholic fatty liver disease 
NASH       Non-alcoholic steatohepatitis 
N-Cor       Nuclear receptor co-repressor 
NEFA       Non esterified fatty acid 
NC        Negative control 
N-CoEx   Nuclear receptor co-repressor / co-
activator exchange factors    
NLS       Nuclear localization sequence 
NZB       New Zealand Black 
NZO       New Zealand Obese 
ONPG       Ortho-Nitrophenyl-β-galactoside 
PEI       Polyethylenimine 
PCR        Polymerase chain reaction 
PIC       Protease inhibitor cocktail 
P/S        Penicillin-Streptomycin 
qPCR        Quantitative Real-Time PCR 
REE       Resting energy expenditure 
RISC       RNA induced silencing complex 
RNA        Ribonucleic acid 
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RNAi       RNA interference 
Scd1       Stearoyl-CoA desaturase 
SDS       Sodium dodecyl sulfate 
Sec       Second 
shRNA      Short hairpin RNA 
SMRT  Silencing mediator for retinoid and 
thyroid hormone receptors 
TBL1       Transducin ß like 1 
TBLR1      Transducin ß like 1 related 
TBP       TATA binding protein 
TG Triglyceride 
TSC22D4 TGF ß-stimulated clone (TSC) 22 
domain family protein 4member   
UCP       Uncoupling protein 
UV       Ultraviolett 
VCP        Valosin containing protein 
VLDL       Very low density lipoprotein 
WAT       White adipose tissue 
WB        Western-Blot 
WHO       World Health Organization  
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